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Summary of study 
Background:  Negative symptoms are present already during the first episode of psychosis, are often 
treatment resistant and contribute significantly to functional decline in psychotic disorders. Negative 
symptoms can be enduring or fluctuate and are associated with poor cognitive function. The limited 
progress in the development of effective treatments for negative symptoms has recently prompted 
studies of the different symptoms making up the negative symptom complex (apathy, flat affect, 
anhedonia, alogia) as one way forward. Kraepelin believed that apathy played an important role in 
poor functioning, a belief still held today. Despite the importance given to apathy, there are only four 
studies investigating apathy in schizophrenia, and none are of first episode patients. Apathy is a 
symptom that has been studied in other brain disorders and has there been found to be associated 
with poor executive function and poor functioning.  Validated scales such as the Apathy Evaluation 
Scale (AES) are used for its assessment, but it has not been tested for use in first episode patients. 
The aim of this thesis is to gain more knowledge about apathy in first episode patients by testing the 
psychometric properties of the AES, followed by an analysis of the frequency, predication, stability, 
clinical-, and neuropsychological correlates of apathy and its  association to functioning at baseline 
and one year follow up.   
Methods:  One hundred and four first episode patients consented to participate in the study and 
were assessed with an extensive clinical and neuropsychological battery. Factor analysis, correlation, 
Students’ t-test, ANOVA, paired sample t-test and multiple linear regression were the statistical 
methods used.   
Results: The AES was found to have sound psychometric properties in the first episode patients and 
the abbreviated 12-item AES-C-Apathy was used in the subsequent studies. At baseline 50% and at 
follow up 40% of all patients were considered clinically apathetic. The schizophrenia spectrum 
patients had the highest mean apathy score both at baseline and at follow-up. Thirty percent had 
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enduring high levels of apathy over the first year. This group consisted of  greater number of males, a 
longer duration of untreated psychosis (DUP), and a greater likelihood of a schizophrenia spectrum 
diagnosis. There were fewer in remission and they had poorer functioning.  Apathy correlated 
significantly only with tests of executive function and working memory, and the association was 
independent of depression and level of medication. Apathy was significantly associated with poor 
functioning both at baseline and follow-up. 
Conclusions: Apathy can be reliably assessed with the AES-C-Apathy in first episode patients. Apathy 
is a frequent symptom and has a strong association with poor functioning both at baseline and at 
follow-up in first episode patients. Those in danger of high apathy levels at follow-up, and hence poor 
functioning,  can be identified with the baseline variables of being of male gender, a long DUP, a 
schizophrenia spectrum diagnosis and a high baseline  AES-C-Apathy score, results  that may have 
implications for early detection strategies.  As in other brain disorders apathy was associated with 
poor executive function,  implying a possible common underlying mechanism across disorders.      
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Concepts, synonyms and abbreviations 
Definitions of concepts 
Apathy: Lack of motivation not attributable to diminished level of consciousness, cognitive 
impairment, or emotional distress  
Disorder:  A functional abnormality in mental or physical health that interferes with a person`s life. 
Functioning: Daily life functioning in the areas of independent living, social and family life, work or  
studies and recreational activities 
Neuropsychiatric symptom:  Mental symptoms attributable to diseases of the nervous system   
Psychosis: Lack of insight into the occurrence of hallucinations and delusions  
Symptom: Something that indicates a physical disorder 
 
Synonyms  
Apathy/avolition/amotivation/lack of motivation 
Cognitive function/neurocognitive function 
First episode psychosis/first episode 
Negative symptoms/negative syndrome/negative symptom complex 
 
Abbreviations   
 AES:  Apathy Evaluation Scale 
AES-C: Clinical version of the AES 
AES-S: Self rated version of the AES 
AES-C-Apathy: The abridged 12 item clinical version of the AES 
CI: Confidence Interval 
DSM- IV: Diagnostic and Statistical Manual of Mental Disorders, version 4 
DUP:  Duration of untreated psychosis 
GAF: Global Assessment of Functioning Scale 
GAF-F: Functioning score of the split version of GAF 
GAF-S: Symptom score of the split version of GAF 
 ICD-10:  International Classification of Disease, version 10  
NIMH -MATRICS: The National Institute of Mental Health project on Measurement and Treatment  
                                Research to Improve Cognition in Schizophrenia 
PANSS: Positive and Negative Syndrome Scale 
PAS: The Premorbid Assessment Scale  
SANS: The Scale for Assessment of Negative Symptoms 
SCID-I/P: Structured Clinical Interview for DSM- IV-TR AXIS I disorders, Patient edition 
SD: Standard Deviation 
TOP study:  Thematically Organized Psychosis Research study 
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1. Introduction 
The onset of psychotic disorders usually occurs between the ages of 15 and 30 at a time when people 
are about to start a life of their own.  After the acute episode is over, from 50 to 75% experience 
problems with daily functioning, impeding a return to normal life with possible lifelong disabilities (1-
4).  Why this occurs is not fully understood and is of great concern (5-8).  
Psychotic disorders are characterized by the presence of delusions and hallucinations, but can 
present with a wide range of symptoms related to different areas of mental functioning: thought, 
affect, cognition and behavior (4).  This heterogeneity has challenged the understanding of which 
symptoms are central to psychotic disorders and to the development of functional difficulties. Thirty 
years ago the most common symptoms were clustered into two main categories; positive and 
negative symptoms (9-11).  Positive symptoms included symptoms of “excess“ mental functioning:  
delusions, hallucinations and thought disturbance (12).  Negative symptoms are those of “reduced” – 
or diminished mental functioning:  apathy (lack of goal-directed behavior), anhedonia (reduced 
experience of pleasure), blunted affect (reduced emotion expression) and alogia (diminished speech 
output)(12). Negative symptoms are found to have a stronger association to poor functioning than 
positive symptoms (4;6;13), although   cognitive dysfunction  also plays a major role (14-16).  
There was great optimism for better understanding, along with better treatment and outcome, when 
the positive-negative distinction was first introduced (12). Treatment for positive symptoms are 
effective; with up to a 70% remission rate (4;17). Unfortunately, the same is not found for negative 
symptoms (8;18;19), and the conclusions are that effective treatment for negative symptoms is still 
lacking (6;7;20).  One way forward, suggested by the consensus statement from the National 
Institute of Mental Health project on Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (NIMH –MATRICS) (6) and others (7;21-23),  has  been to gain more knowledge of the 
different negative symptoms that underlie the negative symptom construct. Negative symptoms are 
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already found at the onset  of psychosis (18;24-30) and the functional disabilities seem to be 
established during the first years of illness (31-33). Hence , studies of the different negative 
symptoms should start with the first episode of psychosis.     
Apathy is one of the negative symptoms where more knowledge has been specifically asked for 
(22;23;34-36). The importance of apathy was first pointed out by Kraepelin who considered apathy 
to play a major role in the detoriorating course of schizophrenia (37).  However, despite the 
importance denoted to apathy, only four studies are identified addressing this negative symptom 
(38-41).  
Apathy is well studied in other brain disorders, and has here been found associated with poor 
functioning (42-45).  Only one study has explored the relationship between apathy and functioning in 
psychosis (39).  This study, conducted in patients with an already long duration of illness, found that 
apathy was more strongly associated with poor functioning than other symptom  areas.  Samples 
with chronic disease can bias the conclusions, since several secondary phenomena  related to 
treatment and long-term institutionalization  can affect the results. Therefore, the results from early 
phase samples are often of more value. There is no study on apathy in first episode psychosis, and 
this is the aim of the present study.  
2. Background  
2.1 Psychotic disorders  
Psychotic disorders have a lifetime prevalence of 1-3% (46) and are characterized by a prominence of 
delusions or hallucinations (psychotic symptoms). In the Diagnostic and Statistical Manual of Mental  
Disorders fourth edition  (DSM-IV)schizophrenia and other psychotic disorders consist  of 9 different 
diagnostic categories (47). Of these, schizophrenia, schizophreniform -, schizoaffective-, delusional-, 
brief psychotic disorder, and psychosis not otherwise specified (NOS) are the disorders most studied.  
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Table 1 in the appendix shows the different diagnostic groups and diagnostic criteria as given in the 
DSM IV (47).  
2.1.1 Schizophrenia 
Schizophrenia is the most prevalent of the psychotic disorders with a prevalence among adults 
ranging between 0.5 to 1.5 % (47).  It has been described throughout history, is recognized in almost 
all cultures and under study worldwide in all countries with a mental health service. Kraepelin was 
the first to describe it as a separate diagnostic entity among the psychotic disorders (37).  
Schizophrenia often gives rise to great suffering both for the patient and for the family involved 
(48;49).  It is one of the most serious illnesses a psychiatrist can treat, and with its early onset and 
long lasting functioning disabilities it is one of the most costly disorders for society, estimated to be 
1% of the Gross National Budget in Norway (26 billion Norwegian kroner in 2009) (50).   
Schizophrenia is currently considered a brain disorder of complex genetic and environmental 
interaction, the cause of which is still unknown (51).  Changes in brain volume, brain signaling and 
brain functioning are found on the group level for patients with schizophrenia and underlines 
schizophrenia as a brain disorder (4),  with the most consistent findings found within the prefrontal 
and  temporal cortises and subcortical structures (4). The correlation between underlying neural 
mechanisms to symptoms in schizophrenia is complex and the relationship between underlying 
pathophysiology and clinical symptoms is weak.  Cognitive dysfunctions are thought to be more 
directly linked to the underlying pathology than clinical symptoms and are considered a core feature 
of the disorder (52;53).  
The development of schizophrenia is divided  into a premorbid - , a prodromal -, and a period with 
full-blown psychotic symptoms (54). Psychotic symptoms can be present for a short or long period 
before treatment of the first episode is initiated (54). Recommended treatments for schizophrenia 
are both psychopharmacological and psychosocial (4;46;55;56).  Different results exist regarding the 
long term prognosis for schizophrenia depending on follow-up time and criteria used (57). A 
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systematic review of the literature found that 42% have a good outcome, 35% intermediate and 27% 
a poor outcome (4)  with  5-15% being fully recovered both for symptoms and functioning (57).    
2.1.2 First episode psychosis  
There is currently a worldwide focus on the first episode of psychosis  and on getting people as early 
as possible into treatment (58). The development of symptoms propelling people to seek treatment 
can be of short duration and start acutely or insidiously over a long time period (59). The presenting 
symptoms can vary between either openly delusional beliefs and disturbed behavior in need of acute 
hospitalization, or with a more insidious onset characterized by retracting from friends or falling out 
of studies or work, making it harder to intervene (60;61). This period, the duration of untreated 
psychosis, is shortened to DUP in the international literature. DUP can be of days, weeks, months 
and, for some, even years, (54) defined as the period from when clear, psychotic (=positive) 
symptoms appear until the initiation of adequate treatment (54;62).  This great variability in 
presenting symptoms and course challenges the diagnostics in the early phases of illness. This is one 
of the reasons for including the whole range of psychotic disorders, and also major affective 
disorders, in studies involving first episode psychosis (63;64).  Depending upon the population under 
study, the frequency of the different diagnostic groups in a first episode sample will vary; with 
around 50-60% being diagnosed with schizophrenia or schizophrenia spectrum psychosis at first 
contact (64;65). 
A long DUP is found associated to poor functioning in numerous studies (66-68) and this is the 
background for the world-wide implementation of early intervention (69) and detection clinics (70). 
The effort directed at shortening of DUP is mostly concentrated around awareness of positive 
symptoms, despite the finding that a long DUP is also associated with negative symptoms (67;71). 
The effect of  early intervention  is currently reviewed (72). The current results imply a need for a 
more differentiated focus, and that  negative symptoms may also need to be targeted in order to 
improve outcome (61).   
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2.2 Positive and negative symptoms of psychotic disorders  
Hippocrates may have been the first to describe what we today call positive and negative symptoms 
when he described madness to be of two kinds; one quiet, and one noisy (73).  The concept of 
positive and negative symptoms is not new, and was first used in the late eighteenth century by 
different physicians trying to describe, and understand, what they observed as two different states, 
or stages, of psychotic symptoms (74).  At that time, they believed that some symptoms represented 
a relatively pure loss of functioning  (negative symptoms), while other symptoms such as delusions 
and hallucinations, represented an exaggeration of normal functioning and were  understood as 
release phenomena when the primary function was lost (positive symptoms).  The term “negative 
and positive symptoms”  was introduced to psychiatry by the French psychiatrist Cleramboult  
around 1942, but did not come into use in the English speaking world before the 1970s (75).  In 
modern psychiatry, it was Nancy Andreasen who coined the term  “negative and positive symptoms” 
and who developed and validated scales for their assessment (12;76).  She based her work on the 
hypothesis published by Crow in 1980 on schizophrenia being of two types. Type I was equivalent to 
“acute schizophrenia” and characterized by a good prognosis and with positive symptoms, and Type 
II was equivalent to the “defect state “ and characterized by negative symptoms with a graver 
prognosis (77).   
Different scales are used for assessment of positive and negative symptoms, such as the Brief 
Psychiatric Rating Scale (BPRS) (78) , Scale for the Assessment of Positive Symptoms (SAPS) (12), 
Scale for the Assessment of Negative Symptoms (SANS) (12) and the Positive and Negative Syndrome 
Scale (PANSS) (79). The positive-negative dichotomy for symptoms in psychotic disorders has 
survived despite different factor analyses suggesting that a three-dimensional model consisting of 
positive, disorganized and negative, better represent the heterogeneity of symptoms (80;81).  Also, 
other factorial solutions of up to five (82;83) and eight dimensions (84) have  been found, but no 
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consensus exists, and no new scales have been developed.  Instead, different factorial solutions that 
represent  symptom dimensions are used from one study to the other.   
2.2.1 Positive symptoms 
Positive symptoms are made up of the symptoms of delusions, hallucinations and thought disorders, 
and are used synonymously with psychotic symptoms.  The clinical picture of one who is having 
delusions, hallucinations or thought disorders is of one having lost contact with reality; often 
describing their reality as disturbing and scary. Positive symptoms are the hallmark for psychotic 
disorders in the two most used diagnostic systems, the DSM-IV (47) and the International 
Classification of Disease, Tenth revision (ICD-10) (85). Their prominence above other symptoms is 
used to differentiate psychotic disorders from other mental disorders.  Further differentiation within 
psychotic disorders is based on their duration; other co-occurring symptoms and functional decline 
(see Table 1 in the Appendix for differentiation). Psychotic symptoms can also be present in other 
mental disorders such as affective disorders, but their presence is brief compared to the key 
symptoms of the disorder. Positive symptoms are used for identification of psychosis in both 
prodromal and early intervention studies, and a cut-off score is used as the crossing line from 
prodromal - to fully present symptoms (86). The length of DUP is based on any one of the positive 
symptoms being present.     
2.2.2 Negative symptoms 
There is no consensus about which symptoms make up the negative symptom complex (6).  Blunted 
affect and alogia were the negative symptoms described by Crow (10) and in the DSM–III  only flat 
and grossly inappropriate affect are included (87).  Nancy Andreasen expanded this by including 
avolition-apathy (reduced will), anhedonia, asociality (reduced interest in social relationships), and 
inattention (76).  Also, some authors include stereotyped thinking and motor retardation in the 
concept (88).  
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The clinical picture of negative symptoms is harder to define than positive symptoms because they 
are a continuum of normal behavior and assess complex human functioning that is reduced. The 
description of what symptoms encompass the negative symptom complex throughout the history of 
psychiatry is difficult to follow from one author to another.  Like the term “negative symptoms”, the 
names assigned to describe these complex behaviors have often been  reduced to one word, such as 
“process symptoms” (89) or “psychomotor poverty syndrome” (90) or the “deficit syndrome” (91). 
These words are not in common use and do not describe well what symptoms or behavior they 
represent.  Kreapelin may have had the best description when he stated the following:  “Dementia 
praecox consist of a series of states, the common characteristics of which is the peculiar destruction 
of the internal connections of the psychic personality.  The effects of this injury predominate in the 
emotional and volitional spheres” (37). He followed up on this, and both emotions and volition are  
among the psychic symptoms he listed as characteristics of dementia praecox (37).  
Negative symptoms are most comprehensively assessed by the SANS (76) and the PANSS negative 
subscale (79), but the two scales differ in their number and content of items (92).  The SANS consists 
of 24 items divided among five subscales representing the different negative symptoms of alogia, 
affective flattening, apathy-avolition, anhedonia and inattention.  The PANSS negative subscale 
consists of seven items and the items are not defined in such a way that they clearly represent the 
different negative symptoms as is found in the SANS.  Another challenge is that the PANSS scoring is 
based mostly on observation, while the SANS is a mixture of interview, observation and patients’ 
reports. New scales for assessment of negative symptoms have, therefore, been asked for (6).    
How negative symptoms develop during the prodromal phase and over the first years of falling ill 
have not been much studied. But negative symptoms are found to be present in the premorbid 
period (93) in patients fulfilling criteria for the prodromal risk syndrome, (94) and to be present at 
the first episode (24;30). One study aimed at reducing DUP with the intervention of a public 
information campaign, found reduced negative symptoms both at baseline (86) and after two years 
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follow-up (95) in the intervention group compared with the non-intervention group, which may 
indicate that negative symptoms undergo development in the pretreatment phase. Level of negative 
symptoms is found to be reduced over the first years of treatment (12;96;97), but relatively less than 
positive symptoms (12;96-98). While a subgroup of patients has stable, enduring, negative symptoms 
during the first year of treatment, for others they may fluctuate and go into remission (21;24;98).  
The association between negative symptoms and poor functioning is found in both first episode – 
and in patients with long-term illness and cross-sectional and longitudinally (4;6). The presence of 
negative symptoms in first episode are found to predict poor functioning both at one(21), two (24), 
four  (99), five (24), seven (100) and ten years follow-up (101), which underlines the importance of 
studying negative symptoms in first episode patients.  
Negative symptoms are thought to be of two kinds:  those that are primary and associated with 
underlying pathophysiology and considered treatment resistant, and those that are secondary to co-
occurring states of depression, delusions, side effects of antipsychotics, illness chronicity  and hence 
treatment responsive (12). It is hard to differentiate the distinction between primary and secondary 
origin in clinical practice (91;102). When considered as secondary, apathy and anhedonia can be part 
of depressive symptoms, and apathy can be a reaction to treatment failure and the effect of living in 
an institution with little stimulation. Asociality may be a symptom of persecutory delusions, and lack 
of affective expression may be due to Parkinsonian side effects of antipsychotics.  The deficit 
syndrome was introduced to help with the distinction between primary and secondary negative 
symptoms (91;103).  The criteria for the deficit syndrome are stability of at least two negative  
symptoms over a one-year period, excluding those with co-occurring depression and side effects of 
medication (103). Reliable diagnosis of the deficit syndrome requires training as well as longitudinal 
clinical observation (102).  It is, therefore, of limited use, especially for persons coming into 
treatment with their first psychotic episode. Recently, a more pragmatic method has been suggested 
by dividing negative symptoms into those that are enduring and those that are non enduring, or 
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fluctuating (104). Patients with enduring negative symptoms, or the deficit syndrome, are found to 
be related to a worse pre-morbid functioning, to be more frequent among males,  -have a longer 
DUP, - poorer functioning, correlating with biological substrates, and to be treatment refractive 
(91;105).  
Negative symptoms are not exclusive for schizophrenia or psychotic disorders and  are also found,  
with less frequency, to be present in severe affective disorders (106;107) and other brain disorders 
such as Alzheimer`s dementia (107;108), traumatic brain disorder (109;110), and epilepsy (111).  
2.3 Cognitive function and psychotic disorders 
Cognitive function refers to how the brain handles information,  its  ability to select and store 
information, and how this information is retrieved and then communicated or acted upon (112).  
Cognitive dysfunction is usually not detected by traditional clinical observation and is, instead, 
assessed by different neuropsychological tests.  Cognitive function is often divided into different 
domains, but studies differ in the description of domains and the tests that represent  them (112). 
The domains most often tested in psychotic disorders are motor function, psychomotor speed, 
attention, working memory, verbal learning, visual learning, and executive function.   
Among psychotic disorders, cognitive dysfunction is extensively studied in patients with 
schizophrenia and considered a core feature of the illness, independent of symptoms and medication 
status (52;113).  Processing speed, attention, working memory, and executive functioning, are the 
cognitive domains that have been the most studied and found to be dysfunctional (53). Cognitive  
difficulties in psychotic disorders seem to be established years before the onset of symptoms and are 
detectable at the first episode (4), are stable and enduring over time, persist after remission of 
symptoms, and do not deteriorate in the chronically ill (4;56).  
The association between cognitive dysfunction and symptoms is mixed, in that most studies find a 
moderately significant association to negative symptoms and no association to positive symptoms 
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(16;88;114).  The association between negative symptoms and cognitive dysfunction is found both at 
the start, and after years of psychosis (115).  However, the direction of the association is not 
established, and different theories and models are proposed (16;115).  
There is a clear and significant association between cognitive dysfunction and poor daily life 
functioning (14;15). This association is found to be stronger than that for negative symptoms  in 
some studies (14),  but not in others (100). Cognitive impairments are largely treatment refractory to 
current interventions, but new promising initiatives are underway.  Cognitive remediation and 
pharmacological interventions are the two areas of most interest (116).   
3.  Apathy  
Apathy is derived from the Greek word “apatheia”, meaning without feeling (117).  In  medical 
dictionaries, apathy is synonymous with indifference, insensibility, and lack of emotion (118).  In 
psychiatry, apathy is mostly associated with the negative symptoms of schizophrenia, but also with 
depression.  Apathy is considered a neuropsychiatric symptom within the field of neurology defined 
as reduced motivation and goal-directed behavior, reflecting lesions of the prefrontal cortex, or of its 
sub-cortical connections (108;119-123). In the field of psychology, extra and intro version are 
personality traits concerned with degree of motivation (124). Apathy is also considered a 
psychological reaction to grave personal bereavement or to witnessing extreme conditions, long 
standing lack of political influence, and living in institutions with little stimulation.  Apathy is  a word 
in common use, referring to some of the above conditions without further specification, and used 
interchangeably with “avolition” and “amotivation” in the literature. With so many different 
meanings, apathy can be hard to study without a clear definition.   
Within the medical field, Marin was one of the first to define apathy (125). He defined apathy as lack 
of motivation not attributed to diminished level of consciousness, cognitive impairment, or 
emotional distress (42;125;126). From this definition he developed the Apathy Evaluation scale (AES) 
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(126).  Other scales have since been developed from this definition such as the Apathy Scale (AS) 
(127), the Apathy Inventory (AI), the Dementia Apathy Interview Rating Scale (DAIRS) (128) and the 
Lille Apathy Rating Scale (LARS)(129).  Apathy is also assessed among other neuropsychiatric 
symptoms in the Frontal System Behavior Scale (FrSbe) (130) and the Neuropsychiatric Inventory 
(NPI) (131).  Table 4.1 to 4.7 in the Appendix shows how apathy is assessed by different scales. 
Apathy was not much studied before these assessment scales were introduced early in the 1990`s 
(42). The AES has been useful across disorders and languages, was translated to Norwegian in 1998, 
and used in several studies of patients with traumatic brain damage (132-134).     
3.1 Apathy and psychotic disorders 
Apathy has been infrequently studied in psychiatry. Only four studies were found in the preparation 
for the current study, all of patients with schizophrenia (38-41).  Kraepelin used volition, avolition or 
apathy interchangeably when he described what he considered to be the key features of 
schizophrenia, and especially when he described what he thought lay behind those with a 
deteriorating and chronic course (37). Bleuler emphasized the lack of affects for the chronic course of 
schizophrenia. His description of this fundamental symptom have a lot in common with Kraepelin`s 
description of volition (135). Kraepelin listed volition as a separate psychic symptom of Dementia 
Praecox and it is also found as such in textbooks following Kreapelin (136).  However, in the current 
major text books of psychiatry, volition is no longer listed as a separate symptom of psychotic 
disorders (4;56). 
 Apathy was also not part of the negative symptoms as they were first described (137), but 
incorporated by Nancy Andreasen into the SANS as a separate subscale named avolition-apathy (76).  
Apathy is not clearly defined in the PANSS negative subscale, but included into the definition of three 
items in the PANSS negative subscale, the N2 (Emotional withdrawal), N4 (Passive/apathetic social 
withdrawal) and N6 (Lack of spontaneity and flow of conversation).  See Table 4.2 in the Appendix for 
further definition of the items.   
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In the four studies of apathy mentioned above, one found apathy associated with poor functioning. 
(39).  Another  found apathy related to prefrontal reduced volume and executive functioning (40), 
while a third studied the effect of motivated behavior, without finding  any difference between those 
with and without apathy (41).  One study, more than 40 years old, found increased activation in 
patients with apathy who were motivated by the staff (38).  All studies have been cross sectional of 
patients with long-term illness, and of a small sample size, New studies have been asked for, and 
currently there are no follow-up studies of apathy.   
3.2 Apathy and other brain disorders  
Apathy is classified as a neuropsychiatric symptom in other brain disorders and has been studied in 
disorders such as Frontotemporal dementia (138),  Alzheimer’s - (139), Parkinson’s - (140), 
Huntington’s disease (141), stroke (142), traumatic brain damage (133;143), multiple sclerosis (144),  
and epilepsy  (145).  Apathy is a primary diagnostic criterion for Frontotemporal dementia (125).  In 
the other brain disorders, apathy is one of several co-occurring neuropsychiatric symptoms, but 
without diagnostic consequences (146).  
Neuropsychiatric symptoms are found to reflect the behavioral effect of lesions and not the 
psychological reaction to being ill (146). There is an increasing focus on neuropsychiatric symptoms in 
different brain disorders because, when present, they often influence the course more than the 
primary symptoms of the disorder (146).  The presence and degree of apathy varies both between 
and within disorders, depending on lesion localization, severity of illness and illness duration (147).  
Apathy is mostly studied in Alzheimer`s disease where it is the most common and persistent 
neuropsychiatric symptom ranging from 30% in a community sample to 80% in nursing home 
residents (43).  In Parkinson`s disease the prevalence of apathy ranges from 17% (148) to 45% 
(149;150), in Huntington`s disease  between 34% to 76% (151), and in traumatic brain damage it 
ranges between 27% (142) to 79% (132;152).  
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The relationship between apathy and depression is of special interest, since they clinically overlap 
(42;153;154). The relationship has been studied in many of the above disorders.  The two have been 
found to be highly correlated but, despite this, found to be independent of each other in Alzheimer`s 
(155;156), Parkinson’s (129;149;157), Huntington`s disorder (141), stroke (142) and traumatic brain 
damage  (152), in that apathy, and not depression, are found associated with functional decline and 
reduced executive function (158;159). Two follow up studies on apathy have been identified.  In 
both, the presence of apathy was related to a worse course (160) and outcome (161).  Apathy may 
also be a reaction to chronic disease. This has been investigated in two studies  comparing the level 
of apathy in patients with Parkinson`s disease to those with dystonia (162) and osteoarthritis  (44), 
finding that the dystonia and ostearthritic patients had a level  of apathy comparable to healthy 
controls.   
3.2.1 Apathy and functioning in other brain disorders 
Apathy is found significantly related to functional impairment when present in all the above 
disorders (43;163-165). In one study of patients with Alzheimer`s disease, the presence of apathy 
was associated with a more rapid progression of dementia and decline of functioning which is not 
found for other neuropsychiatric symptoms (164).  Apathy is also found to predict a more rapid 
conversion from mild cognitive decline to dementia in Alzheimer`s disease (166-171), and suggested 
it be used diagnostically for early identification of Alzheimer`s (166;171).  
3.2.2  Apathy and cognitive function in other brain disorders 
The relationship between apathy and cognitive function has also been extensively studied in the 
brain disorders described above.  Common to studies, is the finding of a consistent relationship 
between high levels of apathy and poorer performance on tests representing executive function 
(44;134;141;150;158;172;173). In addition, significant associations are found to other cognitive 
domains, but the pattern of association is less systematic.  This same relationship has been found in 
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one study of patients with schizophrenia. However, the study sample was small,  of chronic patients, 
and  warranted replication (40).  
3.3 Apathy in healthy volunteers 
In some of the studies above, the level of apathy has been compared with that of healthy control 
persons. For the different control groups the frequency of apathy ranges from 0% (127;174) to 5.4% 
(142;169;175).  
4. Aims and research questions of the thesis 
Negative symptoms are found to be one of the major predictors of poor functioning in psychosis, 
both in chronic and first episode psychosis patients.  There has been limited progress in the 
development of effective treatment of negative symptoms, and poor functioning is still the major 
concern and cost for persons affected with psychosis.  Negative symptoms are not a unitary 
construct, but made up of different symptoms. We have limited knowledge of the different 
symptoms and more knowledge is needed.    
Negative symptoms have been found to be present already at the first episode of psychosis.  In order 
to avoid the possible confounding influence of treatment failure and institutional life, it is of 
particular interest to study the relationship between apathy and functioning in patients with a first 
episode psychosis.  
Apathy is one of the negative symptoms where more knowledge has been especially asked for since 
it is suggested to play a major role in the development of poor functioning.  It has been little studied; 
one reason being the lack of both a clear definition and valid assessment tools. Apathy is a 
neuropsychiatric symptom studied in other brain disorders and several rating scales have been found 
reliable and valid for its assessment.  In these disorders, apathy is found related to poor functioning 
and associated with poor executive function. There are few studies of apathy in psychosis, and they 
are only of patients with long-term illness.  
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Clinical assessments of negative symptoms are challenging because they are based on observation of 
a broad range of reduced behaviors rather than defined symptoms.  The different negative 
symptoms are also differently represented in the two most-used rating scales for negative 
symptoms.  Better and more valid assessment instruments for the different negative symptoms have 
been asked for.  The AES has been used to assess apathy in different brain disorders and in one study 
of patients with chronic schizophrenia.  Before the AES can be used to assess apathy in first episode 
psychosis patients, its use needs to be validated.   
With this background, the aim of the following thesis is to improve our understanding of apathy in 
first episode psychosis patients by answering the following research questions:  
1: Does the Apathy Evaluation Scale have sound psychometric properties when used in a first episode 
psychosis sample?  Does the AES show good discriminative and convergent properties to the five 
factors of PANSS and the PANSS items by correlating highly only with the PANSS negative factor and 
the three PANSS negative items thought to measure apathy (N2, N4 and N6)?  This will be answered 
in Paper 1. 
2: To what degree are first episode psychosis patients apathetic compared to a healthy control 
group? What clinical variables are associated with apathy at start of treatment in first episode?  How 
does apathy, together with other symptom groups as assessed by the PANSS, influence functioning at 
start of treatment?  This will be answered in Paper 2. 
3: Does apathy have the same relationship to neurocognitive function as found in other brain 
disorders?  How do the co-occurring states of depression, positive symptoms or degree of 
medication, influence the relationship?  This will be answered in Paper 3. 
4: How does apathy develop over the first year in first episode psychosis patients?  What predicts 
high levels of apathy at one year follow up?  Is there a group with enduring high levels of apathy over 
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the first year and, if so, what characterizes this group?  How is apathy, together with other 
symptoms, related to poor functioning at the one-year follow up?  This will be answered in paper 4.  
5 Material and Methods 
5.1 The Thematically Organized Psychosis Research (TOP) Study 
TOP is a large translational multicenter research study investigating clinical and biological 
characteristics of psychosis in order to gain more knowledge of the underlying pathophysiological 
mechanisms.  The study is carried out by the University of Oslo in joint collaboration with two major 
hospitals in Oslo and 9 hospitals outside Oslo. All participating hospitals are catchment area based 
and publicly funded with no private specialized service for this group of patients. Patients are 
referred from primary care.  All patients with a possible, or already diagnosed, severe mental 
disorder registered in the specialist health service are asked to participate, and inclusion is still 
ongoing. The TOP study also includes a healthy control group which is randomly selected from the 
population registries of Oslo and from one neighboring community. The controls are contacted by a 
letter giving information about the study inviting them to participate and make contact either by 
phone or by a letter.   
The TOP study was approved by the Regional Committee for Medical Research Ethics (RCMRE) and 
the Norwegian Data Inspectorate in 2004, and the data file has received an Audit Certificate from the 
Center for Clinical Research at Oslo University Hospital, Ullevål in 2007.  This study was approved by 
the RCMRE on the 22nd of April 2004 as a separate study within the TOP study.  
5.2 Ethical and clinical considerations  
In a study with mostly young patients being treated for their first episode of psychosis, consideration 
of ethics and good clinical skills are of  utmost importance to avoid harm and additional burden.  
Therefore, the participants were introduced to the study by different routes.  Brochures and posters 
with general information about the study were placed in the waiting rooms and on the wards.  The 
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appropriate time for asking for participation was discussed in a weekly clinical meeting between the 
clinical staff and researcher. All were informed that declining participation would have no 
consequences for further treatment.   
The TOP protocol includes clinical assessments, neuropsychological tests, fasting blood tests, urine 
sample, and structural and functional magnetic imaging.  The participants have to meet for the 
different assessments over several days.  The clinical assessment, in itself, takes many hours, and for 
many participants it had to be broken up over several days. The clinical assessments were done at 
the site the participant preferred, either in the clinic or at the research office, and transportation by 
taxi was used when necessary.  The patients were not compensated for their participation, with the 
exception of their traveling expenses.  Both the clinical assessment and neuropsychological tests 
were summarized in a written report for use in the clinic.  All patients were asked at baseline about 
the follow up interview.  None declined beforehand, but 18 did not show up. 
5.3 Research Design 
The study is a naturalistic one year follow up study. Three out of the four studies are cross sectional 
and one is a follow-up over one year.    
5.4 Material 
5.4.1 The patients 
This study includes the 104 consenting patients coming into treatment for their first episode of 
psychosis at the Oslo University Hospital or Diakonhjemmet Hospital between July 1st 2004 and 31st 
of June, 2006. The study inclusion criteria were:  a) admitted for treatment of psychotic symptoms 
for the first time either as an out, or an in patient to any of the participating hospitals and with a 
DSM-IV diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, psychosis not 
otherwise specified (NOS), delusional disorder, brief psychosis or major affective disorder with mood 
incongruent psychotic symptoms, b) age between 18 and 65 years, c) understanding and speaking a 
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Scandinavian language, d) having no history of severe head trauma or neurological disease, and  e) 
having an intelligent Coefficient (IQ) score over 70.  Being psychotic was defined as having a rating of 
4 or more on the PANSS items P1, P2, P3, P5, P6 or G9.  Patients were eligible for inclusion up to 52 
weeks following the start of adequate treatment.  Adequate treatment was defined as having started 
treatment in clinically recommended dosage with any antipsychotic medication.  Exclusion criteria 
meant having one or more previous psychotic episodes treated with antipsychotic medication for 
more than twelve weeks or if treatment led to symptomatic remission before twelve weeks.  
One patient withdrew his participation in August 2006, also  wanting his data withdrawn, which came 
into consequence from Paper 2 and onwards, where participating patients were reduced to 103. In 
Paper 3, only those with primary school and higher education in Norway were included, reducing the 
group to 71. Eighteen subjects did not attend the one year evaluation and one met for follow-up, but 
did not complete a full evaluation,  totaling 84 patients (81% of the original cohort) for the analysis in 
Paper 4. Of the 18 subjects who did not meet for the one year assessment, 11 refrained from further 
attendance, five had moved and their current address was not available, two consented to attend, 
but never showed up.  There were no statistically significant differences at baseline between those 
who participated and those who did not participate in the one year follow up regarding sex, age, 
premorbid function, years of education, DUP, diagnostic distribution, degree of drug or alcohol use, 
clinical symptoms or use of antipsychotic medication.   
5.4.2 The healthy control sample 
The healthy control group in this study consisted of 62 individuals who filled out the AES.  Inclusion 
criteria included being born in Norway, holding a Norwegian citizenship, and within an age range of 
18 to 55. The controls were screened with the Primary Care Evaluation of Mental Disorders (176).   
Criteria for exclusion were if they, or any of their close relatives, had a lifetime history of a severe 
psychiatric disorder (schizophrenia, bipolar disorder and major depression), if they had a history of 
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medical problems thought to interfere with brain function (hypothyroidism, uncontrolled 
hypertension and diabetes), or had recent cannabis use (during the last three months). The healthy 
controls received financial compensation for participation of 500 Norwegian kroner. 
Background demographics are presented at the bottom of Table 2 in the Appendix. There were no 
significant differences in gender distribution between patients and the healthy control group, but the 
control group was significantly older than the patients (mean difference 4.7 years, Confidence 
Interval (CI)=1.6 - 0.9, p=.002) and had slightly more years of education (mean difference .9 years; 
CI=0.2 - 1.7, p=.03).  
5.5 Methods 
Background demographics and the results of the clinical assessments for patients at baseline and 
follow up for each of the four studies are given in Table 2 in the Appendix.  An overview of measures 
and statistical procedures used in the four different papers is  given in Table 3 in the Appendix.  
5.5.1 Diagnostic assessment  
Diagnosis was assessed with Structured Clinical Interview for DSM-IV –TR  Axis I Disorders Patient 
Edition (SCID-I/P) (177) both at baseline and after one year.  For the statistical analysis, 
schizophrenia, schizophreniform, and schizoaffective were combined to “Schizophrenia spectrum” 
group; major affective disorder with mood incongruent psychotic symptoms and bipolar I disorder 
with mood incongruent psychotic symptoms were combined to the “Affective psychosis” group, and 
psychosis NOS, brief psychosis and delusional disorder, were combined to “Other psychosis” group.  
At one year follow-up there was a change of diagnostic group for 18 patients (21 %). See Table 2 in 
the Appendix for change within each diagnostic group.  
5.5.2 Assessment of positive, negative and other symptoms 
Symptoms were assessed by the Structural Clinical Interview of the Positive And Negative Syndrome 
Scale (SCI-PANSS) (79). The scale is a 30-item Likert scale ranging between 1-7; where each item is 
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defined and scored according to it being absent or present in the following way: 1=absent, 
2=minimal, 3=mild, 4=moderate, 5= moderate severe, 6=severe, 7=extreme. The PANSS items are  
divided into three subscales, the Positive consisting of 7 P- items, Negative consisting of 7 N-items 
and General psychopathology scale with 16 G-items.   Several factor analyses have since indicated 
that the PANSS measures five symptom dimensions (82;83) . We chose to use Emsley et al’s five 
factor solutions in studies 1, 2 and 4 to represent the symptom dimensions of positive (PANSS-POS) 
consisting of the items P1,P3,P5, P6, G9,G12; disorganized (PANSS-DIS) consisting of the items P2, 
N5, N7, G5, G10, G11, G15; negative (PANSS-NEG) consisting of the items N1, N2, N3, N4,N6, G7,G13, 
G16;  depressive (PANSS-DEPR) consisting of the items G1,G2,G3, G4,G6; and excited (PANSS-EXC) 
symptoms consisting of the items P4,P7,G8,G14 (82). Emsley et al`s solution was used since it is 
based on first episode psychosis patients (82).  In study 3 we only used the PANSS negative and 
positive subscores, and depression was assessed with the Calgary Depression Scale for Schizophrenia 
(CDSS) (178).   
5.5.3 Assessment of apathy  
Apathy was assessed using the Apathy Evaluation scale (AES).  The AES is an 18-item Likert scale with 
a scoring ranging from 0–4 (0 = not at all and 4 = very much).  The AES has three versions with 
identical questions; clinician (AES-C), self (AES-S), and informant rated (AES-I) (126). The clinical 
interview lasts from 15 to 30 minutes; the self-report from 5 to 10 minutes.  Study 1 showed that the 
12-item clinical AES (AES-C-Apathy) gave a better assessment of apathy than the full 18-item version 
in a population with first episode patients (179) and both the abridged clinical (AES-C-Apathy) and 
the self-rated (AES-S-Apathy) were used in the subsequent studies.   In Table 4.1 in the Appendix the 
12 items making up the abridged version are kept in white. For the control group, we only used the 
self-report form. We used a score of 27 on both the AES-S-Apathy and AES-C-Apathy as the cut-off 
value for being clinically apathetic.  This score is based on the distribution of the healthy control  
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group(180), and is the sum of the mean AES-S-Apathy score and two standard deviations 
(18+8.6=26.6~27) .  
Training was supervised by two experienced clinicians that had previously used the scale in other 
patient groups (132), and reliability testing of AES-C was done by scoring of live interviews of random 
study patients.  The inter rater reliability using the Intra Class Coefficient (ICC1-1) of Shrout and Fleiss 
and was 0.98 (95% CI 0.92–0.99) for the AES-C.  
5.5.4 Assessment of alcohol and drug use  
We used the Clinician`s Alcohol and Drug use Scale which separately measures drug and alcohol use 
for the last six months (181).  The scoring goes from 1-5, where 1 = no use, 2 = use without 
impairment, 3 = abuse, 4 = dependence and 5 = dependence with institutionalization.  
 5.5.5 Assessment of daily dose of antipsychotic medication 
The Daily Dose of Antipsychotic medication (DDD-AP) was measured using the World Health 
Organization Collaborating Center for Drug Statistics Methodology (182).  Two patients at baseline 
and four at the one-year follow up used first- generation antipsychotics.  All others used second 
generation antipsychotics.  
5.5.6 Assessment of side effects of medication 
We used The Committee on Clinical Investigations under the Scandinavian Society of 
Psychopharmacology (Utvalg for Kliniske Studier) side effect scale for psychotropic drugs (UKU) (183).  
Only the subscale for the presence of neurological (UKU-neuro) or autonomic (UKU-autonom) side 
effects was used in the present study.  The UKU-neuro consists of 8 items and the UKU-autonom 
consists of 11 items. Each item is rated from 0 - 3 (0= not or doubtfully present; 1= present to a mild 
degree; 2= present to a moderate degree; 3= present to a severe degree).  
5.5.7 Premorbid functioning assessment  
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Premorbid functioning was assessed with the Premorbid Adjustment Scale (PAS) (184).  The 
premorbid phase was defined as the time from birth until 6 months before the onset of psychosis.  
The premorbid phase is divided into four life periods: childhood (up to 11 years), early adolescence 
(12–15 years), adolescence (16–18 years) and adulthood (19 years and beyond).  The scoring ranges 
from 0–6, with 0 indicating the best level of functioning, and 6 the worst.  Several studies have 
confirmed two basic dimensions in the PAS: social (PAS-Social cluster) and academic (PAS-Academic 
cluster) (185;186).  We used the method described by Larsen et al when calculating separate sum 
scores for PAS-Social cluster and PAS-Academic cluster functioning (185) and the method by 
Simonsen et al to calculate change scores for social (PAS-Social-change) and academic functioning 
(PAS-Academic-change) (187).   
 5.5.8 Assessment of functioning 
We used the function score from the split version of the Global Assessment of Functioning scale 
(GAF-F) to measure change in global functioning (188). The split version has been found to 
discriminate well between symptoms and function (189) and has been used in other studies of first 
episode psychosis (95). The GAF-F is a continuous scale ranging from 1–100, where 1 is the lowest 
functioning , and 100 is the best, with each 10 point being defined; i.e. 31-40: poor functioning in two 
life areas, 41-50: poor functioning in one life areas; 51-60 moderate functional difficulties.   
5.5.9 Neuropsychological assessments 
A comprehensive neuropsychological battery of tests was administrated to all participants by 
psychologists or psychology students trained in clinical neuropsychology.  The tests cover domains 
shown to be sensitive to the cognitive dysfunction of psychosis (113;190): motor function (Grooved 
Pegboard) (191), psychomotor speed (Digit Symbol from WAIS-III) (192), attention (Digit Span 
forwards  from WAIS-III) (192), working memory (Letter Number Span from WAIS-III) (192), verbal 
learning (California Verbal Learning Test; CVLT-II) (193), visual memory (Rey-Oesterrieth Complex 
Figure Test) (194) and executive function.  For the executive function domain, several tests from the 
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Delis-Kaplan Executive Function System (D-KEFS) (195) were included in order to enable the 
investigation of the association of apathy with three different aspects of executive function; 
initiation, set shifting and inhibition.  Initiation was assessed with Semantic fluency and Phonetic 
fluency (from the Verbal Fluency test) (195).  Set shifting was assessed with Category Switching (also 
from the Verbal Fluency test) (195), whereas inhibition was measured with the third trial on the 
Color-Word Interference test (the “Stroop” condition) (195).  
Premorbid IQ was assessed with a Norwegian Research version of the National Adult Reading Test 
(NART) (196); and current IQ with Wechsler Abbreviated Scale of Intelligence (WASI; ) (197).  All 
participants showed adequate neuropsychological test effort indicated by two errors or less on the 
forced recognition trial of the CVLT-II.  
5.5.10 Procedures 
All participants gave written informed consent to participate.  The investigators in the study 
completed the common training and reliability program in the TOP study.  SCID-I/P training was 
based on the training program by University of California in Los Angeles (UCLA)(198).   For DSM-IV 
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0.94).  Inter-rater reliability with Intra Class Coefficient [(ICC) 1.1] for the different PANSS subscales 
was : PANSS positive subscale 0.82 (95% CI 0.66–0.94) PANSS negative subscale 0.76 (95% CI 0.58–
0.93), PANSS general subscale 0.73 (95% CI 0.54–0.90) and for GAF-F 0.85 (95% CI 0.76–0.92).   
5.6 Data and statistical analyses 
Preliminary analyses were performed to examine distribution of each variable and all data was 
inspected for skewness and linearity. Logarithmic transformation (ln) was used for data that was not 
normally distributed.  Only the variable representing the duration of untreated psychosis was 
transformed.  All analyses were checked for the influence of outliers. One extreme outlier being 4 
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Standard Deviations (SD) outside the group mean on the verbal fluency test was taken out of the 
analysis in paper 3.  All tests were two tailed. The statistical significance level was pre set to p <.05, 
except in paper 1 where it was preset to p < .01 due to multiple testing and in paper 3 to <.02 for 
some analyses for the same reason.  
Descriptive statistics were presented as mean and standard deviation (+SD) or median and range for 
non-normally distributed data.  Observed values are presented with actual number (n) and percent 
(%) and adjusted values in means and with a 95% confidence interval (CI).  Independent t- tests were 
used to test the difference in continuous variables between two groups. One-way analysis of 
variance (ANOVA) with post-hoc Scheffe`s test was used to test for differences with more than two 
groups. Paired sample t-test was used to analyze the difference between measures at baseline and 
one year follow up.  Mann-Whitney U test (U) was used to test for differences between groups for 
non parametric data. Differences between categorical data were analyzed with Chi->@YZ
The strength of the linear relationships between variables was calculated using Pearson product 
moment correlation (r) and Chi square test for categorical variables.  The relationship between one 
continuous dependent variable and multiple independent variables was analyzed by linear regression 
methods and only independent dependent variables with a significant (p <.05) correlation with the 
dependent variable under study were included.  The final models were checked for violations of 
assumptions and for the effects of outliers and influential observations.  Psychometric properties of 
the AES were analyzed using principal factor analysis with Varimax rotation. All data was analyzed 
using the Statistical Package for Social Sciences (SPSS) for Windows, first version 12, later version 15, 
SPSS Inc., Chicago, Il, USA.  For an overview of the statistical methods used in each paper see table 2. 
6. Results and summary of the four studies 
Paper 1: Assessing apathy: The use of the Apathy Evaluation Scale 
in first episode psychosis 
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 Background and aims:  Recently there has been a renewed interest in the different symptoms that 
constitute the negative symptoms in schizophrenia and new scales for their assessment have been 
asked for.  Apathy is one of the negative symptoms in focus.  The Apathy Evaluation Scale (AES) with 
its clinical version (AES-C) is one of the most used scales for assessment of apathy in an 
interdisciplinary context, but it has never been used in a population with a first episode of psychosis. 
The main aims of this study were to examine the psychometric properties of the AES-C.    
Material and method: A total of 104 patients with a first episode psychosis from the ongoing 
Thematic Organized Psychosis Research (TOP) study were included in this study.  The psychometric 
properties of the AES-C were tested by correlation and factor analysis.  The Positive and negative 
Syndrome Scale (PANSS) was used to test the convergent and discriminative properties of the AES-C.  
A five-factor model of PANSS was used to represent the positive, disorganized, negative, depressive 
and excitatory symptoms of psychosis.  
Results: Factor analysis of the AES-C identified a three-factor model that gave the most clinically 
meaningful model, accounting for 53% of the variance in the AES-C. The major subscale was made up 
of 12 of the original 18 items, all items concerned with motivation, initiative and interests.  It was 
named AES-C-Apathy.  The six items left for the two minor subscales were concerned with insight 
and social contacts.  The three subscales had from modest (r =.37) to no intercorrelation (r = .04), 
indicating that the three scales measure different dimensions.  The AES-C-Apathy subscale showed 
satisfactory internal consistency with a Cronbach`s alpha of .90 and a high inter-rater reliability (ICC) 
of .98 (CI .92 - .99), which was also found for the AES-C.  The AES-C-Apathy had good discriminative 
and convergent properties towards the five factors of PANSS, by correlating strongly (r = .6) only with 
the PANSS-negative, modest (r = .3) with the PANSS-disorganized and weakly with the three other 
PANSS factors of -positive (r =.2) , - depressive (r=.2) and  -excitement (r=.03). The AES-C-Apathy also 
had good convergent and discriminative properties with the 30 different PANSS items, by correlating 
strongly (r=.6, r =.5) with only the three apathy-related items of the PANSS negative subscale, N2 
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(r=.6), N4 (r =.5) and N6 (r=.5), and with modest (r=.3) to no correlation (r=-.06) with all the other 27 
PANSS items.  The two minor subscales had weak correlations with the PANSS negative items, as well 
as most other PANSS items, and were not used in the subsequent work.   
Conclusion:  The conclusion drawn from this study is that the abridged AES-C, the AES-C-Apathy, had 
sound psychometric properties and can be used to assess apathy in the ongoing work of refining the 
negative symptoms in first episode psychosis.    
Paper 2: Apathy and functioning in first episode psychosis  
Background and aims:  Negative symptoms, more than other clinical symptom areas of psychosis, 
have been found to be one of the major predictors of poor functioning both in chronic and first 
episode patients. It is currently of great concern that there are no established treatments for 
negative symptoms. Negative symptoms are not a unitary construct but made up of different 
symptoms, mainly apathy (reduced goal directed behavior), anhedonia (reduced experience of 
pleasure), flat affect (reduced affective expression), asociality (reduced interest in social contacts), 
and inattention.  The recent NIMH-MATRICS statement on negative symptoms, and others, has 
suggested that one way forward in developing more effective treatments, is to get a better 
understanding of  the different negative symptoms. Apathy is one of the symptoms where more 
knowledge has been requested.  The aim of this paper is, thus, to study apathy closer in first episode 
patients  to determine to which degree first episode psychosis patients, at the start of treatment, are 
apathetic compared to healthy controls, if schizophrenia spectrum patients have higher levels of 
apathy than other diagnostic groups, and which patient characteristics  relate to higher levels of 
apathy, and to what degree apathy contributes to functional loss. 
Material and Method:  The study includes 103 first episode psychosis patients and 62 healthy 
control persons participating in the TOP study.  Apathy was assessed with the abridged Apathy 
Evaluation Scale (AES-C-Apathy).  Other clinical symptoms were assessed with the Positive and 
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Negative Syndrome Scale (PANSS).  The PANSS five-factor model was used in the subsequent 
analyses. Functioning was assessed with the split version of Global Assessment of Functioning scale 
(GAF-F). Correlation and multiple linear regression analysis were used as the statistical methods to 
answer the research questions.  
Results:  There was a significant difference in mean AES-C-Apathy score between controls and first 
episode patients (18.0 +4.3 vs. 27.7+7.2; p<.001).  The cut off score for being clinically apathetic was 
set to 27, defined as 2 SD above the mean score of AES-S-Apathy for the healthy control group.  With 
this cut off score, slightly more than 50% of FEP patients were found to be clinically apathetic 
compared to 3% of healthy controls. There was a significant diagnostic group difference in AES-C-
Apathy score, with the highest mean score in the Schizophrenia spectrum group.  Only the difference 
between the Schizophrenia spectrum – and Other psychosis group was statistically significant.  Of the 
clinical variables only premorbid childhood social functioning, change in premorbid social functioning 
and PANSS -disorganized symptoms had a significant association to the AES-C-Apathy score; 
explaining 18% of the variance.  Multiple regression analysis revealed that of the entire five PANSS 
symptoms, only PANSS-positive together with AES-C-Apathy had a significant independent 
association to global functioning as assessed with GAF-F.  Together they explained 37% of the 
variance in the GAF-F score.   
Conclusion:  The conclusion drawn from this study is that apathy is a prevalent symptom in first 
episode patients already from the start of illness, and significantly different from what was found in 
the healthy control group.  We also found that apathy was significantly associated  with poor 
functioning. The significant association between apathy and functioning at this early stage of illness 
points to the need of evaluation and attention of apathy for tailoring the right treatment- and 
rehabilitative goals.   
Paper 3:  Apathy is associated with executive functioning in first episode 
psychosis  
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Background and aim: The underlying nature of negative symptoms in psychosis is poorly 
understood. Negative symptoms have repeatedly shown to have a significant association to cognitive 
deficits. Cognitive deficits are found to be more closely associated to underlying brain pathology than 
symptoms.  Therefore, an exploration of the association between the different negative symptoms 
and cognitive function may aid the search for the mechanisms behind negative symptoms. Apathy, 
one of the negative symptoms, is also a common symptom in other brain disorders and its 
association to cognitive dysfunction, in particular executive dysfunction, is well documented. A 
significant association was found in the  relationship between apathy and cognitive function  
explored in one former study of chronic patients with schizophrenia. But the study was of small 
sample size and of patients being ill for many years. This study investigates the association between 
apathy and cognitive function in first episode patients, with the hypothesis that apathy, also in first 
episode patients, is more strongly associated with tests representing executive function than tests 
representing other cognitive domains, and that the relationship is unrelated to depression, positive 
symptoms or degree of medication.  
Material and methods:  Seventy-one first episode patients with a fluent understanding of Norwegian 
were assessed with an extensive neuropsychological test battery.  Level of apathy was assessed with 
the abridged Apathy Evaluation Scale (AES-C-Apathy) and other symptoms with the Positive and 
Negative Syndrome Scale (PANSS).  Correlation and multiple linear regression analyses were the 
statistical methods used to answer the research questions. 
Results:  We found that the AES-C-Apathy was significantly associated with tests from the executive 
domain representing initiation [Semantic fluency (r = .37, p < .01), Phonetic fluency (r = .25, p < .05)] 
and working memory [Letter Number Span (r = .26; p =< .05)]; but not other neurocognitive domains 
or tests.  Co-occurring depression, positive symptoms or use of antipsychotic medication did not 
significantly influence these results. 
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Conclusion: The conclusion drawn from this study is that apathy in first episode psychosis has a 
specific significant association to executive function which replicates the findings in chronic patients 
with schizophrenia and is the same as what is also found in other brain disorders.  
Paper 4: Apathy in first episode psychosis patients: one year follow up 
 
Background and aims: Negative symptoms are often more treatment resistant and, thus, among the 
most severe symptoms of psychotic disorders. Enduring high levels of negative symptoms has  a 
stronger association to poor functioning than those that are transient and are found to be enduring 
already from the first episode of psychosis.  We do not know how this applies to the different 
negative symptoms.  At baseline, more than half of the 103 first episode patients were considered 
apathetic and apathy was found strongly associated with poor functioning.  The aim of this study is, 
therefore, to study how apathy develops from baseline to the one year follow up; to study what 
predicts high levels of apathy at one year; if there is a subgroup of patients with enduring high levels 
of apathy; and the association between apathy, other symptoms, and functioning. 
Material and methods: Eighty-four first episode patients were assessed both at baseline and after 
one year with the abridged clinical version of the Apathy Evaluation Scale (AES-C-Apathy).  A cut off 
score of 27 was used for being clinical apathetic. The Positive and Negative syndrome scale (PANSS) 
was used to assess other symptoms.  Functioning was assessed with the split version of the Global 
Assessment of Functioning Scale (GAF-F). Correlation, t-tests, ANOVA, paired sample t-tests and 
multiple linear regression analyses were used as the statistical methods to answer the research 
questions.  
Results: We found that 40% of the first episode patients were apathetic at the one-year follow up 
compared to 50% at baseline.  The mean level of apathy decreased significantly for the whole group 
from baseline to follow up.  At the diagnostic group level the decrease was only statistically 
significant for the Other psychosis, not for the Affective or the Schizophrenia spectrum group.  At 
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both time points, the Schizophrenia spectrum group had the highest mean level of apathy and the 
Other psychosis group the lowest.  There was a statistical significant difference in mean level of 
apathy between the diagnostic groups in such a way that at baseline this difference was only 
significant between the Schizophrenia spectrum and Other psychosis group, but at follow up the 
difference was statistically significant between all three groups (Schizophrenia >Affective 
psychosis>Other psychosis).  High levels of apathy at the one year follow up were best predicted by 
high levels of apathy at baseline, a long DUP and a Schizophrenia spectrum diagnosis.  Twenty five 
(30%) of the 84 FEP patients had enduring high levels of AES-C-Apathy.  The enduring apathy group, 
compared to the non-enduring group, consisted of statistically significantly more males (80% vs. 
51%), more had a DSM-IV Schizophrenia spectrum diagnosis (88% vs. 53%), they had a longer DUP 
(52 vs. 24 weeks), were less likely to have remission of positive symptoms at baseline (16 % vs. 49%) 
and at one year (36% vs. 73%), had a lower mean GAF-F score both at baseline (37 vs. 49) and at one 
year (42 vs. 59) and fewer  were working or studying both at baseline and follow up.  We also found 
that at the one year follow up AES-C-Apathy had a strong association to poor functioning, as 
measured by GAF-F, and showed the strongest relationship when analyzed together with other 
PANSS symptom areas.   
Conclusion: The conclusion drawn from this paper is that apathy is most prevalent and enduring in 
the Schizophrenia spectrum group and that the clinical variables characterizing the group with 
enduring apathy are the same as found for enduring negative symptoms. Also, at the one-year follow 
up, apathy was strongly associated to poor functioning. This underlines the significance of assessing 
apathy in first episode patients and supports the recent initiatives to include negative symptoms in 
early intervention studies.  The study also supports the value of assessing the individual negative 
symptoms as suggested by the NIMH-MATRICS consensus.     
 
39 
 
7. Discussion of methodological issues 
7.1 Reliability 
Clinical assessments were done by three experienced clinicians; two medical doctors and one 
psychologist.  All took part in the TOP training program to secure reliability for DSM IV, GAF and 
PANSS.  In addition, the three of us met regularly to discuss inclusion issues and performed 
assessments together to increase reliability beyond the formal training.  We were especially trained 
by the research group who had long experience in the use of the AES at the Oslo University hospital, 
Rikshospitalet in Oslo.  All took part in the reliability testing of AES, which was done from taped 
interviews with participating patients. The inter rater reliability, ICC, ranges from 0.73 to 0.82 for the 
PANSS subscales, and was 0.85 for GAF-F and 0.98 for the AES-C. The above are the accepted 
standards required for research (180),  which  provide our assessments and data with good quality 
support.    
7.2 Biased assessments  
We had no opportunity to do a blind assessment of apathy from other assessments where apathy 
may play a role, such as the PANSS and GAF. All clinical assessments were done by the same clinician 
and scoring bias may be present.  However, the sum score of the AES was blinded and was not 
calculated before all assessments were in the database.  At the one-year assessment none of the 
baseline assessments were available. The PAS, which is used to assess premorbid functioning, is 
based on retrospective information from both the patient and parents.  The PAS scoring may, 
therefore, be due to recall bias and reduced information since we were not able to interview the 
parents and results must be interpreted with this in mind.   
7.3 Validity of the difference between apathy and functioning  
Since the influence of apathy on functioning was one of the main aims of the study, it was important 
to ensure that the assessment covered by the AES-C-Apathy and GAF-F did not overlap.  The AES is a 
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semi-structured interview aimed at assessing the patient’s personal experience of initiative, 
motivation and interests.  Each of the 12 items is scored independently of each other, on a Likert 
scale ranging from 1 to 4, and the sum score is based on the individual scores for each item.  There is 
no additional global apathy score.  The GAF-F assesses work, studies and daily life performance.  The 
scoring is based on the clinicians’ observations and facts about being unable to work, strained 
relationships and dependence on others for daily living.  The GAF-F score is a global score and can be 
any score between 1 and 100, where each ten points are defined with examples of functional 
difficulties. The GAF-F does not take into account what causes the functional difficulties, and reduced 
initiative and motivation is not used to describe the reduced functioning.   
7.4 Timing of baseline assessments 
Most of the assessments were not part of the clinical routine for any of the participating hospitals 
and, therefore,  the study assessments could not be done before the patient was clinically stable and 
found capable of giving written informed consent. 
 Assessments at baseline were, therefore, not done before symptoms had stabilized, and could be up 
to 52 weeks after start of adequate treatment.  The reason for this was to ensure the appropriate 
time for consent and to include as many participants as possible, especially those  predominantly ill 
with lack of insight and long lasting florid psychotic symptoms.  Baseline is calculated, therefore, not 
when treatment starts, but at first assessment. This is a problem common to many of the first 
episode studies. The consequence of this may be that the difference between the two assessment 
points regarding symptom level will be less, since many patients are already stabilized at the baseline 
assessment.  This has an advantage of eliminating some of the acute phase variation, which is often 
noise in the statistical analyses.   
7.5 Challenges in statistical methods 
Correlation, differences between groups, and linear regression are the statistical methods mostly 
used to analyze the data in this thesis.  In addition, a factor analytic method was used in Paper 1.  
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Both inequality in group sizes and the relative small sample size (ranging between 71 in Paper 3 and 
104 in Paper 1) make the data vulnerable to outliers and skewed data, which can give rise to both 
Type I and Type II errors.  This needs to be considered when interpreting results, and is commented 
on separately in the result section.  Many of the results presented in the thesis are based on cross 
sectional analyses, and, hence, cannot  speak to  the direction of significant associations. In Study 4, 
follow up data was  used in order to be able to answer the direction of the association between 
apathy and other variables.     
7.6 Representativity and generalizability 
The study consisted of 104 patients included over a 2-year period, consecutively recruited as they 
were coming in to treatment for their first episode of psychosis.  In the first year, recruitment of 
patients was from two hospitals in Oslo covering one catchment area each (Ullevål : population = 
190.000, Diakonhjemmet : population = 115.000) and the second year, a third hospital joined 
covering a third catchment area (Aker: population = 160.000). The three clinicians worked closely 
with the clinical staff at each hospital, assuring that all potential patients were asked.  The study is 
based on written informed consent and no records were kept of those declining to participate. 
Thirty-seven patients were included the first year (total population 305.000) and 67 the second year 
(total population 480.000), which gives a yearly incidence of 12/100000 and 14/100000. The former 
Treatment and Intervention in Psychosis study (TIPS) recruited from one of the catchment areas 
(Ullevål) from 1997 to 2000, and their incidence range between 12-17 pr 100000 over a four year 
period (86), which is reduced to 11 pr 100000 when only those consenting are included (personal 
communication from professor Svein Friis).  Our incidence rate is thus similar to that of the TIPS 
study.  A  recent review of annual  incidence rates for schizophrenia  found a median of  11.1 / 
100000, with a range of 4.8 to 22.6 (199). Compared to this, our results are in the lower range, since 
only about a half of the sample had a diagnosis of schizophrenia at baseline.  Of the original cohort of 
104, 84 came for the one year follow up assessment giving a response rate of 81 %, which is about 
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the same as the TIPS study and others (200;201). This also adds to the representativety of our data.  
Despite the above limitations, with no record of those declining, and an incidence rate in the lower 
range, we regard our sample as representative for first episode psychosis patients from a large 
catchment area, and that the results can be generalized for the whole population of first episode 
patients.   
8. Discussion of main results 
There are seven important finding in the thesis.  The first finding is that the negative symptom of 
apathy can be reliably and validly assessed with the abridged AES, the AES-C-Apathy in first episode 
patients.  The second finding of importance is that high levels of apathy are prominent in first 
episode both at baseline assessment and after one year, and with the highest mean AES-C-Apathy 
score in the Schizophrenia spectrum group.  Thirdly, high levels of apathy are strongly associated 
with poor functioning both at baseline and follow up.  The fourth is that AES-C-Apathy correlates 
significantly only with tests of executive function and working memory, and not other neurocognitive 
tests.  The fifth finding is that, despite significant associations between apathy and co-occurring 
states, these associations seem to have only minor to no influence on the significant associations 
between apathy and executive function and GAF-F. The sixth is that the group with enduring apathy 
consists of significantly more males, more have a diagnosis within the schizophrenia spectrum 
patients, have a longer DUP, fewer are in remission, and they have worse functioning both at 
baseline and at follow up.  Lastly, that high levels of apathy at the one year follow up  are best 
predicted by baseline level of apathy, a long DUP and a Schizophrenia spectrum diagnosis. 
8.1 The negative sub symptom of apathy can be reliably and validly assessed 
with an abridged AES, the AES-C-Apathy in first episode psychosis patients  
This is the first study testing the psychometric properties of the clinical version of the AES-C in first 
episode psychosis patients.  We found good psychometric properties with good internal consistency 
and convergent and discriminative ability, much the same as was found in the study by Kiang et al in 
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patients with chronic schizophrenia (39), in the original study by Marin and others (126;164;202)and 
as concluded in a recent review of the AES-C (203).  Factor analysis gave one main factor, also the 
same as found in other studies (126;132;164;204), and with considerable overlap between the 
studies in the retained items in the main factor (126;202).There is also overlap between the studies 
in that items of social contact and insight belong to the minor factors (126). As can be seen in Table 
4.1 and 4.4-4.7 in the Appendix, the content of the items in the AES-C-Apathy corresponds well with 
other apathy scales in use, which supports the use of the abridged version rather than the full length 
scale.   
There are some methodological limitations in our psychometric testing of the AES that need to be 
mentioned.  As discussed under 7.1.2, one limitation is that the clinical interviews and scoring of the 
AES and the PANSS were done by the same person.  Ideally, they should have been assessed by 
different persons blind to the  others’ ratings in order to secure unbiased scoring of apathy.  This 
weakness is partly compensated by the fact that there are clear differences between the PANSS and 
the AES in how they assess apathy.  As can be seen in Table 4.2 in the Appendix, PANSS has not 
assigned a specific item to apathy; rather apathy is a one of several words used to describe a 
behavior in three of the seven items making up the PANSS negative subscale.  Also, assessment of 
PANSS negative items is based mainly on observation, while the AES actively asks the patient about 
his/her experience.  The second limitation is that we have not tested the specificity and sensitivity of 
our cut off score against a clinical judgment of apathy.  Our cut off score is based on standard 
deviation from a mean value with a cut off score of 27 for the abridged AES-C-Apathy, corresponding 
to 39 for the full AES-C.  Different methods can be applied when determining a cut off score for a 
scale (180).  Different cut off scores for the AES-C exist, ranging from 34 (132;134;152) to 41 (202) 
and  one study has found difficulties with finding a clinically meaningful cut off score for the AES 
when validated against a clinical judgment  (204).  Our cut off score is, thus, in the upper end, 
securing that we have not over reported the frequency of apathy. But with so many different cut off 
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scores for the AES, there is a clear need for a clinical validation. Despite the above shortcomings, the 
AES was found to have sound psychometric properties and we recommend the use of the abridged 
AES-C-Apathy for assessment of apathy in first episode patients.  
8.2 High levels of apathy are prominent in first episode psychosis patients and 
with the highest level in the Schizophrenia spectrum group   
Fifty percent of the first episode psychosis patients at baseline, and 40% at one year follow up, were 
considered clinically apathetic.  Fennig et al is the only other study found to report on the frequency 
of apathy in first episode psychosis patients at baseline (27), finding that 61% of patients diagnosed 
with schizophrenia had a score of 3 or more on the SANS avolition/apathy subscale.  For the other 
diagnostic groups the frequency ranged between 53% in the schizoaffective to 13% in the bipolar 
group.  Our frequency is slightly lower than in this study, but we report for the whole group of 
patients, and not on the diagnostic level, which can partly explain this difference.  
The Schizophrenia spectrum patients had the highest mean AES-C-Apathy score both at baseline and 
follow up of the three diagnostic groups.  The score was statistically significantly higher compared to 
the Other psychosis group both at baseline and follow up, and to the Affective group at follow up.  
These results must be interpreted with some caution due to small group size for the Affective and 
Other psychosis groups.  However, the differences are in line with Fennig et al, who also found the 
highest rating of apathy in patients with schizophrenia compared to other diagnostic groups (27).  
Apathy can also be a psychological reaction to extreme life events and is often thought of as a 
reaction to being seriously ill.  Schizophrenia is a serious illness, and the high level of apathy in this 
group could reflect such a reaction.  But there are also good reasons to think that some of the 
difference in mean apathy score reflects differences in underlying psychopathology.  Apathy is 
considered to reflect lesions of the prefrontal cortex and there is much evidence for schizophrenia 
being a disorder involving the prefrontal cortex, more so than for affective disorders and other 
psychosis.  Also, other brain disorders have found significant differences in apathy score between site 
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of lesion and diagnostic groups and with higher scores when the prefrontal cortex is involved. 
(126;132). However, these differences need to be further explored before a firm conclusion can be 
drawn.  
8.3 Apathy is strongly associated with poor functioning both at baseline and 
at one year follow up 
This study replicates the significant association between high levels of apathy and poor functioning, 
as was found in the study by Kiang et al of chronic patients with schizophrenia (39).  The significant 
association between negative symptoms and poor functioning in first episode patients is well 
documented (21;24;101).  In our study, PANSS negative symptoms had a significant association to 
GAF-F in the univariate analysis, but in the multivariate analysis, with AES-C-Apathy as one of the 
other independent variables, the association became non significant.  Apathy thus shows a stronger 
association to functioning than the broader measure of PANSS negative factor, which points to the 
advantage of assessing the different negative sub symptoms and not the concept as a whole.  We 
were not able to assess the other negative symptoms at the same level of accuracy, and hence study 
their interaction and how they differently may contribute to poor functioning.  This is a problem with 
most of the current literature in the area, and needs to be explored further, before we fully can 
understand the interaction between negative symptoms and poor functioning.    
Different studies of apathy in other brain disorders, regardless of assessment instruments used, have 
found significant associations to functioning (205). These results, together with our study, point to 
the importance of apathy and a possible common influence from apathy on functioning across 
disorders.   
This study did not explore the influence of other variables, together with apathy, on poor 
functioning. Poor premorbid functioning (187;206), long DUP(71;207) and cognitive dysfunction 
(100;208) have all been found to be significantly associated with poor functioning.  The combined 
influence also needs to be explored further to give a more complete picture of the mechanisms 
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behind poor functioning.  Despite these shortcomings, the repeated results, both at baseline and 
follow up,  underline the importance of apathy for functioning in psychotic disorders, a relationship 
that many have proposed to be important, but that has not been studied in first episode psychosis 
patients before.    
8.4 High levels of apathy correlate significantly with tests of executive 
function and working memory, and not other neurocognitive tests 
This study replicated the findings of Roth et al of a significant association between apathy and 
executive dysfunction in patients with psychotic disorders (40), this despite the two studies using 
different measures, and the Roth et al study including chronic patients.  In both studies, the 
association was independent of degree of depression.  This same association between apathy and 
executive functioning has also been found in numerous studies in other brain disorders (43;44;134).  
Several of these studies used the verbal fluency tests (43;44;141;150), and in two of these studies 
apathy was assessed with the AES(44;150), eliminating the challenge of comparing results between 
different scales.  This supports the idea of a common underlying psychopathology for apathy across 
disorders involving the prefrontal cortex, since executive function tests are found to reflect lesions 
from this area.  It needs to be explored if other negative symptoms have the same associations.    
8.5 Apathy and co occurring depression, positive symptoms and medication  
In clinical work, apathy is difficult to differentiate from depression, reaction to psychotic symptoms, 
degree and side effects of medication and the presence of apathy has often been considered 
secondary to these states (125;154). This thesis did not aim at fully studying the interaction between 
apathy and co-occurring states but, rather, their influence upon significant associations between 
apathy and general functioning, apathy and cognitive function, and in prediction of apathy at one 
year. The bivariate relationship between AES-C-Apathy and the variables representing these co-
occurring states [PANSS-depressive, PANSS-positive, DDD (daily dose of antipsychotic medication), 
UKU-neuro (neurological side effects) and UKU-Autonom (autonomic side effects)] was mostly found 
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to be significant, and the strength of the association increased from baseline to follow up.  Despite 
the correlation, their influence on the significant association between apathy and executive function 
and GAF-F , was found to be minor or mostly negligible.  This results adds to the importance of 
treating apathy as an independent symptom in need of its own treatment interventions (209).  
Of special interest has been the relationship between apathy and depression (153;154).  Studies have 
shown that  one can be both apathetic and depressed at the same time, and that many who are 
apathetic are not depressed and vice versa (132;155;210-212).  The affective component of psychosis 
was highlighted by E. Bleuler, who addressed anhedonia and flat affect as a fundamental symptom of 
psychosis (135).  Only recently have the interaction between affect and motivation been explored 
(22;36), relationships that are of special interest for a better understanding of the underlying 
mechanisms of negative symptoms.   
8.6 Patient characteristics of the group with enduring apathy  
We found that 30% of the first episode patients had enduring high levels of apathy over the first 
year. Enduring high levels of negative symptoms over the first year for first episode patients has been 
investigated in three previous studies (21;28;98).  Of these, Malla et al’s study required the stability 
of one of the SANS sub scores and found a rate of 23% (98).  The Gerbaldo et al study found a rate of 
31% (28), applying the Scale for the Deficit Syndrome (SDS) (103), which requires stability of two sub 
symptoms.  Depending on method used, Edwards et al have found the rate of enduring negative 
symptoms to vary between 3.8% to 41.2% (21).  Our results are, thus, within the range of what is 
found in other studies.  Our study is best compared with Malla et al’s, since they  studied only one of 
the negative symptoms.  However, none of these studies specified which of the different negative 
symptoms  were enduring and direct comparison, therefore, is difficult.  
The group with enduring apathy is characterized by having significantly more males, a longer DUP, a 
greater likelihood of Schizophrenia spectrum diagnosis, fewer subjects in remission of positive 
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symptoms, and poorer functioning; the same patient characteristics as found for enduring negative 
symptoms and the deficit syndrome.   
This study was  not designed to specifically answer the question of a primary versus a secondary 
origin for apathy, but many of the results in our study give argument for considering apathy to be a 
primary symptom reflecting underlying psychopathology and not a symptom of co-occurring states.  
The findings supporting this are that a)premorbid social functioning were significantly associated 
with high apathy levels at baseline b) a high proportion of patients already at start of treatment are 
considered apathetic,  c) the differences between the diagnostic groups and that the highest mean 
level of apathy were found among patients with Schizophrenia spectrum diagnosis, d) the group with 
enduring high levels of apathy has the same characteristics as found for enduring negative symptoms 
e) the significant association to executive functioning as also found in other brain disorders 
independent of co-occurring states; and, lastly, f) its strong and independent association to poor 
functioning both at baseline and follow up. Enduring negative symptoms have, for a long time, been 
synonymous with “permanent ” and being resistant to treatment, while secondary have led to focus 
on the co-occurring states and more or less ignoring the presence of negative symptoms (61).  This 
dichotic division of the negative symptoms needs to be challenged.  In our study, the level of apathy 
was reduced at follow up for half of those with high levels at baseline,indicating that apathy is a 
symptom that changes.  What makes it change is important to study further.  Many factors can 
contribute to the endurability. One suggested mechanism is the experience over time that gives rise 
to negative expectancy appraisals (213-215). To seek further support for this may be a fruitful path in 
the search for effective treatments of apathy and also other negative symptoms (216), since 
development of new medications may be years away.  
8.7 High levels of apathy at the one year follow up is best predicted by 
baseline level of apathy, a long DUP and a Schizophrenia spectrum diagnosis 
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Signs or symptoms that can predict the outcome are of importance for medical practice and 
allocation of resources.  This study found that high apathy levels are strongly associated with poor 
functioning and that those with enduring high levels of apathy had a poorer outcome than the other 
patients. High apathy levels at one year were best predicted by a high baseline level of apathy, long 
duration of untreated psychosis and a schizophrenia spectrum diagnosis.  Being male had significant 
predictive influence before controlling for baseline levels of apathy.  The same variables that predict 
high levels of apathy at follow up are similar to variables that characterize those with enduring levels 
of apathy.  Identifying those at risk of enduring apathy, and hence poor functioning , should 
therefore be possible  at the start of treatment.  This may be important in allocating resources to 
those most in need and explaining why motivation is low and goals take a longer time to achieve.  
9 Strengths and weaknesses of the study 
The study has it strength in being catchment-area based in a health system where no private 
hospitals operate; thus securing representativity for the population seeking help.  We have both 
cross sectional - and follow up data, and a high response rate.  Assessments were done by a few, all 
with long clinical experience and with extensive training through the whole inclusion period and with 
good to excellent inter rater reliability for tested assessment instruments. The AES was found to have 
the same good psychometric properties as found in other patient populations making it a reliable 
scale for assessment of apathy. The main weakness is that inclusion was possible up to a year after 
start of adequate treatment, and that we were not able to study other negative symptoms and how 
they interact with the results found for apathy.  Also, the lack of recording those that declined to 
participate is a weakness.  Apathy and functioning should  have ideally been assessed by 
independent raters, and the cut off score of the AES-C-Apathy for being apathetic needed a clinical 
validation.  
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10 Implications 
10.1 Clinical implications  
This study has important clinical implications in that it shows that apathy can be reliably assessed,  is 
present already at an early phase of treatment in first episode psychosis patients, has serious 
influence on functioning, and that the group in danger of enduring apathy and poor functioning can 
be identified early after coming into treatment. The AES has a larger potential to serve as a starting 
point for interventions than the PANSS negative subscale.  Apathy is a common phenomenon that 
can be discussed with the patient, whereas the PANSS ratings do not adequately communicate  
which behavior is diminished.  The assessment of apathy can be used in the clinical work with the 
patient, his family and others, in the understanding of why goals may be hard to achieve, and to find 
new ways of increasing motivation. The consequences of high levels of apathy are most obviously 
seen in the group with enduring high levels of apathy, where only 16% were studying or working at 
start of treatment compared to 54% in the non-enduring group.  It is reasonable to think that apathy 
is present in the premorbid phase and that focusing not only on positive symptoms but also on 
negative symptoms in early intervention programs is needed.  There is currently no evidence-based 
treatment for apathy (209).  Different interventions are currently being tested in other brain 
disorders that could also work as models for the field of psychiatry, since at least some of the 
underlying mechanisms seem to be of common origin.    
10.2 Implications for future work 
The finding of a reliable scale to assess apathy in psychotic disorders has implications for the ongoing 
work in exploring the boundaries between the individual negative symptoms and their underlying 
mechanisms.  Apathy may also serve as a more proximate target to pathophysiology than the 
negative symptoms, and has the advantage of being a clinically feasible and easily measured concept.  
It can thus serve as a test case for new drugs and specific psychosocial interventions.  This study also 
shows that much is still unknown regarding the nature of apathy.  Why does the level of apathy 
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fluctuate for some?  Why is it more enduringly high for others?  At what stage in development of 
psychosis does apathy start to influence functioning?  And is there a common mechanism for all 
patients with apathy that can tell us something more about how the brain works?  But, probably, the 
largest challenge for the future is to implement these results into the clinical work.   
11. Conclusions 
 Apathy can be reliably assessed in first episode psychosis patients with the AES-C-
Apathy, the shortened AES. 
 Apathy is an  important symptom in first episode psychosis patients that needs 
attention from the start of treatment 
o A strikingly high proportion of first episode patients are apathetic at first 
assessment and after one year.  
o High levels of apathy have a strong association to functioning, both at first 
assessment and after one year.  
 The group at risk of high levels of apathy after one year can be identified by having a 
high AES-C-Apathy score at baseline, having a long DUP and a schizophrenia 
spectrum  diagnosis 
 There are strong indications that apathy is a primary symptom reflecting underlying 
pathophysiology and not secondary to other co-occurring states 
o Clinical variables with significant associations to apathy have also been found 
to have significant relationships to underlying pathology 
o Apathy is related to poor executive function   
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o Positive symptoms, depression, degree of medication and side effects do, only 
to a minor degree, interfere with the significant associations between apathy 
and other clinical variables 
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Appendix 
Table 1: Diagnostic criteria for psychotic disorders (DSM-IV) 
Schizophrenia 
     Criteria               A Characteristic symptoms: Two (or more) of the following, each present for a significant portion of time during 
a 1-month period ( or less if successfully treated):  
1)delusions 2) hallucinations 3)disorganized speech 4)grossly disorganized or catatonic behavior 5)negative 
symptoms i.e., affective flattening, alogia and avolition 
                                B Social occupational dysfunction: for a significant portion of the time since the onset of the disturbance, one or 
more major areas of functioning such as work, interpersonal relations, or self care are markedly below the 
level of achieved prior to the onset ( or when the onset is in childhood or adolescence, failure to achieve 
expected level of interpersonal, academic, or occupational achievement 
                                C Duration: Continuous signs of the disturbance persist for at least 6 months. This 6-month period must include 
at least 1 month of symptoms (or less if successfully treated) that meet Criterion A and may include periods of 
prodromal or residual symptoms. During these prodromal or residual periods, the signs of the disturbance 
may be manifested by only negative symptoms or two or more symptoms listed under criterion A presented 
in an attenuated form. 
                                D Schizoaffective and Mood disorder exclusion: Schizoaffective Disorder and Mood disorder with psychotic 
features have been ruled out because either 1) no Major depressive, Manic  or Mixed Episodes have occurred 
concurrently with the active phase symptoms; or 2) if mood episodes have occurred during active phase 
symptoms, their total duration has been brief relative to the duration of the active and residual periods 
                                E Substance/general medical condition exclusion: The disturbance is not due to the direct physiological effects 
of a substance (e-g drug of abuse, a medication) or a general medical condition 
                                F Relationship to a pervasive Developmental disorder: If  there is a history of Autistic Disorder or another 
pervasive Developmental disorder, the additional diagnosis of Schizophrenia is made only if prominent 
delusional or hallucinations are present for at least a month (or less if successfully treated) 
Schizophreniform disorder 
                                 A Criteria A,D and E for schizophrenia are met 
                                 B An episode of the disorder (including prodromal, active, and residual phases) lasts at least 1 month but less 
than 6 months 
Schizoaffective Disorder 
                                 A An uninterrupted period of illness during which, at some time, there is either a Major Depressive Episode, a 
Manic Episode, or a Mixed Episode concurrent with symptoms that meet Criterion A for schizophrenia 
                                 B During the same period of illness, there have been delusions or hallucinations for at least 2 weeks in the 
absence of prominent mood symptoms 
                                 C Symptoms that meet criteria for a mood episode are present for a substantial portion of the total duration of 
the active and the residual periods of the illness 
                                 D The disturbance is not due to the direct physiological effects of a substance (e.g. a drug of abuse, a 
medication) or general medical condition.  
Delusional disorder 
                                 A No bizarre delusions (i.e. involving situations that occur in real life, such as being followed, poisoned, infected, 
loved at a distance, or deceived by spouse or lover, or having a disease) of at least 1 month`s duration 
                                 B Criterion A for Schizophrenia has never been met 
                                 C Apart from the impact of the delusion(s) or its ramifications, functioning is not markedly impaired and 
behavior is not obviously odd or bizarre 
                                 D If mood episodes have occurred concurrently with delusions, their total duration has been brief relative to 
the duration of the delusional periods 
                                  E The disturbance is not due to the direct physiological effects of a substance ( e.g., a drug of abuse, a 
medication) or a general medical condition 
Brief Psychotic Disorder 
                                 A Presence of one of the following 1)delusions  2)hallucinations 3)disorganized speech 4)grossly disorganized or 
catatonic behavior 
                                 B Duration of an episode of the disturbance is at least 1 day but less than a month, with eventual return to 
premorbid level of functioning 
                                 C The disturbance is not better accounted for by a Mood Disorder with Psychotic features, Schizoaffective 
Disorder, or Schizophrenia and is not due to the direct physiological effects of a substance (e.g. a drug of 
abuse, a medication) or general medical condition 
Shared psychotic Disorder (Folie a Deux) 
                                 A A delusional develops in an individual in the context of a close relationship with another persons (s), who has 
an already-established delusion. 
                                 B The delusion is similar in content to that of the person who already has the established delusions 
                                 C The disturbance is not better accounted for another Psychotic Disorder (e.g. Schizophrenia) or a Mood 
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Disorder With Psychotic Features and is not due to the direct physiological effects of a substance (e.g. a drug 
of abuse, a medication) or general medical condition 
  Psychotic Disorder Due to a General Medical Condition              
                                 A Prominent hallucinations or delusions  
                                 B There is evidence from the history, physical examination, or laboratory findings that the disturbance is the 
direct physiological consequence of a general medical condition 
                                 C The disturbance is not better accounted for by another mental disorder 
                                 D The disturbance does not occur exclusive during the course of delirium 
Substance-Induced Psychotic Disorder 
                                 A Prominent hallucinations  or delusions 
                                 B There is evidence from the history, physical examination, or laboratory findings of either 1) or 2): 
1) the symptoms in Criterion A developed during, or within a month of Substance Intoxication or Withdrawal 
2) medication use is etiologically related to the disturbance 
                                 C The disturbance is not better accounted for by a Psychotic Disorder that is not substance induced. Evidence 
that the symptoms are better accounted for by a Psychotic Disorder that is not substance induced might 
include the following: the symptoms precede the onset of the substance use (or medication use); the 
symptoms persist for a substantial period of time ( e.g. about a month) after the cessation of acute 
withdrawal or severe intoxication, or are substantially in excess of what would be expected given the type or 
amount of the substance used or  the duration use; or there is other evidence that suggests the existence of 
an independent non-substance-induced Psychotic Disorder 
                                D The disorder does not occur exclusively during the course of a delirium 
Psychotic Disorders not Otherwise Specified 
                                  This category include psychotic symptomatology about which there is inadequate information to make a 
specific diagnosis or about which there is contradictory information, or disorders with psychotic symptoms 
that do not meet criteria for any specific Psychotic disorder 
                                 1 Postpartum psychosis that does not meet criteria for Mood Disorders with Psychotic features, Brief Psychotic 
Disorder, Psychotic Disorder Due to a General Medical Condition, or Substance-Induced psychotic Disorder 
                                 2 Psychotic Symptoms that have lasted for less than 1 month but have not yet remitted, so that criteria for Brief 
Psychotic Disorders are not met  
                                 3 Persistent auditory hallucinations in the absence of any other features 
                                 4 Persistent non-bizarre delusions with periods of overlapping mood episodes that have been present for a 
substantial portion of the delusional disturbance 
                                 5 Situations in which the clinical has concluded that the Psychotic Disorder is present, but is unable to 
determine whether it is primary, due to a general medical condition, or substance induced 
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Table 2: Demographics for each study 
 
Data givens as either N(%) or mean (+SD) Paper 1 Paper 2 Paper 3 Paper 4 
Patients (N) 104 103 71 84 
Male  61 (57 %) 60 (58 %) 37(52 %) 50 (60 %) 
Age  27.3 (+7.7) 27.3 (+7.7) 27.4 (+8.1) 27.4 (+8.2) 
Years of education  13.0 (+2.7) 13.0(+2.7) 12.5 (+2.7) 12.8 (+2.7) 
Living alone   63(89%)  
Premorbid Functioning     
  PAS social cluster childhood 
  PAS social cluster early adolescence 
  PAS social cluster adolescence 
 1.4(+1.6) 
1.3(+1.4) 
1.7(+1.5) 
 1.5(+1.6) 
1.1(+1.3) 
1.5(+1.3) 
  PAS academic cluster childhood 
  PAS academic cluster early adol 
  PAS academic cluster adolescence 
 1.6(+1.2) 
2.0(+1.3) 
2.3(+1.4) 
 1.7(+1.2) 
1.9(+1.4) 
2.1(+1.4) 
Duration untreated psychosis  weeks   
(median range) 
35 (1-1040) 35(1-1040) 30 (1-1040) 35(1-1040) 
Hospitalized for psychosis 69 (66%) 69(67%)  53 (63%) 
  Baseline Baseline Baseline Baseline      /            1 year 
Diagnostic categories      
    Schizophrenia Spectrum  
       Schizophrenia  
       Schizoaffective 
       Schizophreniform 
 57(55%) 
45(43.7%) 
2(1.9%) 
10(9.7%) 
  36 (51%)     45(54%)                              53(63%) 
35(41.6%)                           45(53.5%) 
     2(2.3%)                                7(8.3%) 
     8(9.5%)                                1(1.2%) 
    Affective Psychosis 
       Major affective 
       Bipolar I 
 17(17%) 
14(13.5%) 
3(2.9%) 
15 (21%)    16(19%)                               17(20%) 
13(15.4%)                           11(13.1%) 
     3(3.6%)                              6 (7.1%) 
   Other psychosis 
       Psychosis NOS 
       Brief Psychosis 
       Delusional disorder 
 29(28%) 
20(19.4%) 
7(6.8%) 
2(1.9%) 
20 (28%)     23(27%)                              14(17%)    
16(19.0%)                               8 (9.5%) 
     6(7.1%)                                   5(6%) 
     1(1.2%)                                1(1.2%) 
AES-C-Apathy 27.1(+7.2) 27.2(+7.1) 27.2(+7.1)    27(+7.4)                            24.9(+6.9) 
PANSS total score  
   PANSS-positive 
   PANSS-disorganized 
   PANSS-negative 
   PANSS-depressive 
   PANSS-excitement 
60.7 (+14.6)    60.9  (+14.5) 
14.7 (+5.2) 
11.1 (+3.6) 
16.5 (+6.6) 
12.4 (+4.1) 
  5.6 (+1.99 
60.5(15.1) 61.6(+15.1)                       53.5(+14.6) 
  15.2(+6.0)                         12.7(+6.3) 
  11.2(+3.7)                         10.4(+3.7) 
  16.9(+6.8)                         15.1(+5.7) 
  12.6(+4.2)                         10.6(+4.2) 
5.5(+1.9)                           5.0(+1.9) 
Alcohol misuse or depend   12 (11.7%)  12(14.3%)                                8(9.5%)   
Drug misuse or depend     22 (21.4%)  18(21.4%)                           15(17.9%) 
Using antipsychotic medication  82(79%) 81(78.6%) 57(80.3) 65(78.8%)                           57(67.8%) 
DDD-AP  1.0(+0.6) 1.1(0.6)   1.0(+0.6)                              0.3(+0.9) 
UKU-neuro      1.1(+1.4)                              0.5(+0.8) 
UKU-autonom      2.2(+2.2)                              2.0(+2.4) 
GAF-S (mean,SD) 42.1(+12.8) 41.9 (+12.7) 42.8 (14.0) 42.4(13.1)                          53.7 (16.5) 
GAF-F (mean, SD) 45.7(+14.0) 45.5 (+12.7) 46.1 (46.1) 45.6(14.1)                          54.3 (15.8) 
Controls (N)   62   
       Male N (%)  28(45%)   
       Age (mean,SD)  32(+9.3)   
       Years of education (mean,SD)  13.9(+1.9)   
AES-S-Apathy (mean,SD)  18.0(+4.3)   
aPAS Premorbid Assessment of  Functioning Scale; b Alcohol and Drug use scale: a score >3 indicate misuse or dependence 
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Table 3: Clinical assessments and statistical methods for each study 
 Paper 1 Paper 2 Paper 3 Paper 4 
Clinical  
measures 
SCID 
PANSS 
AES-C 
 
PAS 
DUP 
SCID 
PANSS 
AES-C 
AES-S 
Alcohol and Drug use scale 
GAF- S /GAF-F  
SCID 
PANSS 
CDSS 
AES-C 
 
PAS 
DUP 
SCID 
PANSS 
AES-C 
Alcohol and Drug use scale 
GAF-S/GAF-F 
UKU 
Design Cross sectional Cross sectional Cross sectional Follow up 
Statistical 
analysis 
Correlation  
Principal factor analysis  
   with Varimax rotation 
Cronbach`s _ 
Correlation 
Differences continuous variables: 
     Independent Students  t- tests 
    ANOVA 
    Paired sample t-test 
Linear regression 
Correlation 
Linear regression 
Correlation 
Differences  continuous variables:  
   Independent Students t-test 
   ANOVA  
   Paired sample t-test 
Group differences: 
   Chi-squared test 
   Mann Whitney U-test 
Linear regression 
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Table 4.1 
AES  Apathy Evaluation Scale 
1 S/he is  interested in things 
2 S/he gets things done during the day 
3 Getting things started on his/her own is important to him/her 
4 S/he is interested in having new experiences 
5 S/he is interested in learning new things  
6 S/he puts little effort into things 
7 S/he approaches life with intensity 
8 Seeing a job through to the end is important to her/him 
9 S/he spends time doing things that interest her/him 
10 Someone has to tell her/him what to do each day 
11 S/he is less concerned about her/his problem 
12 S/he has friends 
13 Getting together with friends is important to her/him 
14 When something good happens, s/he gets excited 
15 S/he has an accurate understanding of her/his problem 
16 Getting things done during the day is important to her/him 
17 S/he has initiative 
18 S/he has motivation 
Table 4.2 
PANSS Negative subscale  
N1 Blunted affect: Diminished emotional responsiveness as characterized by a reduction 
in facial expression, modulation of feelings, and communicative gestures 
N2  Emotional withdrawal : Lack of interest in, involvement with, and affective 
commitment to life`s events 
N3 Poor rapport: Lack of interpersonal empathy, openness in conversation, and sense of 
closeness, interest or involvement with the interviewer 
N4  Passive/apathetic social withdrawal: Diminished interest and initiative in social 
interactions due to passivity, apathy, anergy or avolition. This leads to reduced 
interpersonal involvements and neglect of activities of daily living 
N5 Difficulty in abstract thinking: Impairment in the use of abstract-symbolic mode of 
thinking, as evidenced by difficulty in classification, forming generalizations, and 
proceeding beyond concrete or egocentric thinking in problem-solving tasks 
N6 Lack of spontaneity and flow of conversation: Reduction in the normal flow of 
communication associated with apathy, avolition, defensiveness cognitive deficit.  
This is manifested by diminished fluidity and productivity of the verbal-interactional 
process 
N7 Stereotyped thinking. Reduction in the normal flow of communication associated with 
apathy, avolition, defensiveness, or cognitive deficit. This is manifested by diminished 
fluidity and productivity in the verbal interaction 
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Table 4.3 
SANS Avolition-Apathy Subscale  
1 Grooming hygiene: The patient`s  clothes may be sloppy or soiled, and he or she may 
have greasy hair, body odor, etc 
2 Impersistence at work or school (relative to general population): Based on the 
patient`s age and sex, rate the degree to which the patient has difficulty in seeking or 
maintaining employment, attending school, keeping house or engage in volunteer 
work 
3 Physical Anergia: The patient tends to be physically inert. He or she may sit for hours 
and does not initiate spontaneous activity  
 Global rating of Avoltion-Apathy: Strong weight may be given to one or two 
prominent symptoms if particularly striking 
Table 4.4 
AS  The Apathy Scale  
1 Are you interested in learning new things? 
2  Does anything interest you?  
3  Are you concerned about your condition? 
4  Do you put much effort into things? 
5 Are you always looking for something to do? 
6 Do you have plans and goals for the future? 
7  Do you have motivation? 
8  Do you have the energy for daily activities? 
9 Does someone have to tell you what to do each day? 
10 Are you indifferent to things? 
11 Are you unconcerned with many things? 
12 Do you need a push to get started on things? 
13 Are you neither happy nor sad, just in between? 
14 Would you consider yourself apathetic? 
Table 4.5 
DAIR The Dementia Apathy Interview and Rating 
1 Does s/he seem indifferent to what is going on around her/him? 
2 Does it seem important to her/him to succeed in things s/he tries to do? 
3 Does s/he tend to just sit and do nothing? 
4 Does s/he seem less active? 
5 Is s/he able to keep busy during the day? 
6 Will s/he start activities on her/his own? 
7 Are there things s/he is enthusiastic about? 
8 Does s/he show a full range of emotions? 
9 Does she no longer seem to react to things as much as s/he used to prior to illness? 
10 Does she start conversations? 
11 Is she less spontaneous? 
12 Does she show interest in news about friends and relatives? 
13 Does she suggest things to do for the day? 
14 Does she enjoy things she can do as much as she used to before the illness began? 
15 Is she concerned about how people feel? 
16 Does she seem to care less about finishing things that she has started? 
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Table 4.6 
NPI  Apathy / Indifference subscale 
Has the patient lost interest in the world around him/her? Has he/she lost interest in doing things 
or does he/she lack motivation for starting new activities? Is he/she more difficult to engage in 
conversation or in doing chores? Is the patient apathetic or indifferent?  If yes, proceed 
1 Does the patient seem less spontaneous and less active than usual? 
2 Is the patient less likely to initiate a conversation? 
3 Is the patient less affectionate or lacking emotions when compared to his/her normal 
self? 
4 Does the patient contribute less to household chores? 
5 Does the patient seem less interested in the activities and plans of others? 
6 Has the patient lost interest in friends and family members? 
7 Is the patient less enthusiastic about his/her usual interests? 
8 Does the patient show any sign other signs that he/she doesn`t care about things? 
Table 4.7 
Diagnostic criteria for Apathy  
A: Loss of, or diminished, motivation in comparison to the patient’s previous level of functioning 
and which is not consistent with his age or culture. These changes in motivation may be reported by 
the patient himself or by the observations of others. 
B: Presence of at least one symptom in at least two of the three following domains for a period of at 
least four weeks and present most of the time 
Domain B1: Loss of, or diminished, goal-directed behavior as evidenced by at least one of the 
following: - Loss of self-initiated behavior (for example: starting conversation, doing basic tasks of 
day-to-day living, seeking social activities, communicating choices) - Loss of environment-stimulated 
behavior (for example: responding to conversation, participating in social activities) 
Domain B2: Loss of, or diminished, goal-directed cognitive activity as evidenced by at least one of 
the following: - Loss of spontaneous ideas and curiosity for routine and new events (i.e., challenging 
tasks, recent news, social opportunities, personal/family and social affairs). - Loss of environment-
stimulated ideas and curiosity for routine and new events (i.e., in the persons residence, 
neighborhood or community). 
Domain B3: Loss of, or diminished, emotion as evidenced by at least one of the following: 
- Loss of spontaneous emotion, observed or self-reported (for example, subjective feeling of weak 
or absent emotions, or observation by others of a blunted affect) - Loss of emotional 
responsiveness to positive or negative stimuli or events (for example, observer-reports of 
unchanging affect, or of little emotional reaction to exciting events, personal loss, serious illness, 
emotional-laden news) 
C: These symptoms (A - B) cause clinically significant impairment in personal, social, occupational, or 
other important areas of functioning.  
D: The symptoms (A - B) are not exclusively explained or due to physical disabilities (e.g. blindness 
and loss of hearing), to motor disabilities, to diminished level of consciousness or to the direct 
physiological effects of a substance (e.g. drug of abuse, a medication). 
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Errata 
The printed version of this thesis is a reprint of the originally submitted thesis to the University of 
Oslo.  The following changes (seen in bold) have been made: 
 
1) Thesis 
p   8, line 21: Confidence 
p19, line 24: Table 4.2 in the Appendix 
p20, line   2:  functioning (40), while 
p 23,line 12: PANSS 
p28, line   8:  N4, N6,G7 
p51,line 15: AES-C-Apathy score at baseline, 
p51,line 21: functioning 
 
2)Papers 
Paper 2 
p  8, line   7: G7, G13 and G16 
p13,line 19: Type II error 
 
 Table 1 
“Other psychosis” should be 29, not 27. 
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2Abstract
Objective: To determine which patient characteristics relates to higher levels of apathy,
to which degree first episode psychosis patients are apathetic compared to healthy 
controls and to which degree apathy together with other symptoms including negative 
subsymptoms influences functioning in first episode psychosis.
Method: The study includes 103 first episode psychosis patients and 62 healthy control
persons participating in the Norwegian Thematically Organized Psychosis research study.
Apathy was assessed with the abridged Apathy Evaluation Scale (AES-C-Apathy). Other 
clinical symptoms were assessed with the Positive and Negative Syndrome Scale 
(PANSS). The PANSS five-factor model was used in the subsequent analyses. 
Functioning was assessed with the split version of Global Assessment of Functioning 
scale (GAF-F). 
Results: More than 50% of first episode psychosis patients were found to be clinically 
apathetic compared with healthy controls. Of all clinical variables, only premorbid 
childhood social functioning, change in social functioning and disorganized symptoms 
(PANSS disorganized component) had a significant influence on AES-C-Apathy,
explaining 18% of the variance. Multiple regression analysis revealed that of the entire 
five different PANSS symptoms, only PANSS positive component together with AES-C-
Apathy made significant independent contribution to GAF-F, explaining 37% of the 
variance. Using the same model, only N1 (flat affect) of the different items comprised by 
the PANSS negative component made an independent significant contribution to 
functioning. Conclusion: Apathy is a prevalent symptom in first episode psychosis 
3with a significant association to real life functioning, and its presence and consequences 
should thus be evaluated at the start of treatment.
Keywords: First episode psychosis, apathy, negative symptoms, premorbid function, 
global function, self-assessed function
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4Introduction
The high risk of prominent functional decline makes schizophrenia one of the most 
disabling disorders affecting young people [1,2]. Negative symptoms are found to be one 
of the major predictors of poor functioning across studies both in chronic patients [3-5]
and in patients with first episode psychosis [6,7]. The importance of this area is 
illustrated by the  recent NIMH-MATRICS consensus statement on negative symptoms,
which concluded that there has been limited progress in the development of effective 
treatments [8].  Both the consensus statement and other clinical researchers [9-11] argue 
that we need to shift focus from regarding negative symptoms as a unitary construct and 
instead study the different components or subsymptoms that underlie the symptom area.
The concept of negative symptoms is old [12],  but was re-introduced as a meaningful 
concept at the end of the 1970`s [13] to explain the heterogeneity of symptoms and 
outcome in schizophrenia [14]. We  know that negative symptoms is not a unitary 
construct but a syndrome made up of different subsymptoms, mainly apathy/avolition, 
anhedonia, alogia, asociality, flat affect  and inattention [14]. Our knowledge of the 
underlying mechanisms behind these subsymptoms are limited [8].
Apathy is a neuropsychiatric symptom associated with dysfunction of the prefrontal 
cortex or its subcortical connections [15-17]. Apathy is found to be a common symptom 
in a broad range of neuropsychiatric- or brain disorders such as Alzheimer`s dementia
[18],  Parkinson`s disease [19], Huntington`s diseases [20], and in traumatic brain 
damage [21]. Already Kraepelin considered apathy to be the core symptom of  the 
chronic stages of schizophrenia [22], a view that is also held and emphasized today [23-
25].
5One challenge for the study of negative symptoms and subsymptoms has been the lack of 
valid and reliable rating scales for use in clinical settings [11,26]. The Apathy Evaluation 
Scale (AES) was developed to assess apathy in neuropsychiatric disorders [27] and has 
been widely used in studies of apathy [19,21,28]. In the AES, apathy is defined as “lack 
of motivation or goal directed behavior not attributable to diminished level of
consciousness, cognitive impairment or emotional distress”. The scale has been validated 
for use across different medical disciplines, and recently also for patients with first 
episode of psychosis [29] and chronic schizophrenia [30]. The availability of a well-tried
assessment method for apathy makes it a good candidate for exploration of the 
mechanisms behind the development of negative symptoms.
The clinical importance of negative symptoms more broadly defined is based on their
clear association to functional decline. An increase in knowledge about their underlying 
mechanism will thus aid our understanding of what lies behind the functional decline
itself. To evaluate whether apathy is a good model system for understanding functional 
decline, it is of importance to know whether also apathy as a symptom is associated with 
decreased functioning. Apathy has been found to be clearly related to poor functioning in 
several neuropsychiatric disorders [18,31]. The only existing study addressing the 
relationship between apathy and functioning in schizophrenia, reported that apathy  more 
than other symptoms  predicted poor functioning in a group of chronic patients,  
indicating an association at least in this patient group [30].
However, to avoid the possible confounding influences of treatment failures and social 
defeat in chronic schizophrenia, it is of particular interest to study the relationship 
between apathy and functioning in a first episode psychosis patient group. The aim of the 
6present study is thus to answer the four following questions: Do first episode psychosis 
patients experience higher levels of apathy than persons without psychiatric disorders do?
Do first episode psychosis patients with schizophrenia spectrum disorders have higher 
levels of apathy than patients with other first episode psychosis disorders? What other 
clinical characteristics (outside of diagnosis) are related to apathy in the early treatment 
phase? And finally to what degree does apathy contribute to functional loss in first 
episode psychosis patients?
Material and methods
Participants
Patient group: One hundred and three consecutively recruited first episode psychosis 
patients that had given written informed consent to participate in the ongoing 
Thematically Organized Psychosis research (TOP) study were included in the study. The 
patients were treated for a first episode psychosis between July 2004 and July 2006 in the 
catchment area based out- or inpatient psychiatric units of the three major hospitals in 
Oslo, Norway covering more than two-thirds of the city. Patients were eligible for the 
study if they were between 18 and 65 years, having a DSM-IV diagnosis of 
schizophrenia, schizophreniform disorder, schizoaffective disorder, psychosis NOS, 
delusional disorder, brief psychosis or major depressive- or bipolar I disorder with mood 
incongruent psychotic symptoms. All the clinical assessments, including assessment of 
premorbid function and the duration of untreated psychosis were made after the start of 
adequate treatment and in a stable phase; hence, patients could be included into the study
up to 52 weeks after start of adequate treatment. Patients were not included if they had on
any occasion prior to inclusion in the study, been psychotic and treated with adequate 
7doses of antipsychotic medication for more than 12 weeks or until symptomatic remission 
if that was achieved before 12 weeks (in those cases they would be considered as patients 
treated for  their second episode). The duration of untreated psychosis was measured 
from the first week with psychotic symptoms (i.e. having a rating of 4 or more on the 
PANSS items P1, P3, P5, P6 or G9) until the first week of adequate antipsychotic 
treatment, defined as either admission to hospital or starting adequate antipsychotic 
medication. The demographic, diagnostics and symptomatic distribution of the patient 
group is presented in Table 1.
Healthy control group: The 62 persons forming the healthy control group consisted of 
persons randomly selected from statistical records in the same catchment areas as the 
study patients. They were invited to participate by letter. The participants were screened
with the Primary Care Evaluation of Mental Disorders [32], and were excluded if they, or 
any of their close relatives, had a lifetime history of a severe psychiatric disorder 
(schizophrenia, bipolar disorder and major depression), if they had a history of medical 
problems thought to interfere with brain function (hypothyroidism, uncontrolled 
hypertension or diabetes), or had recent cannabis use (used the last three months).
There was no significant difference in gender distribution between the patient group and 
the control group, but the control group was significantly older than the patients (mean 
difference 4.7 years, CI=1.6 - .9, p=.002) and had slightly more years of education (mean 
difference .9 years; CI=.2 -1.7, p=.03) (Table1).
General clinical assessment
Symptoms were assessed by the Structural Clinical Interview of the Positive And
Negative Syndrome Scale (SCI-PANSS) [33]. Repeated factor analyses have
8consistently indicated that the PANSS measures five symptom dimensions, but with some 
variations in the composition of the different dimensions in the different studies [34]. We 
chose to use the components based on Emsley et al’s factor analysis of PANSS since this
analysis was  based on a first episode psychosis sample [35]. The components represent 
positive (PANSS-POS), negative (PANSS-NEG), disorganized (PANSS-DIS) depressive
(PANSS-DEPR) and excited (PANSS-EXC) symptoms. In the follow-up analysis, the 
different items included in the PANSS-NEG (N1, N2, N3, N4, N6, G7, G13 and G16) 
were used to represent aspects of the different subsyptoms of negative symptoms.  
Assessment of apathy
Apathy was assessed by the Apathy Evaluation scale (AES). The AES has several
versions with identical questions but with different respondents; clinical- (AES-C), self-
(AES-S), and informant rated (AES-I) [27]. All three versions have 18 identical questions
to be answered on a likert scale ranging from 0 – 4 (0=not at all and 4=very much).
Example of the questions are: “Are you interested in things?”, “Is it important for you to 
get things done during the day?”, “Do you spend time doing things that interest you?” 
and “Do you feel motivated?” In the self-report form, the respondents make their own 
direct assessments. In the clinician-based form, the respondents are interviewed to
facilitate probing and evaluate the validity of the respondent’s report (since apathy often 
coincides with disorders of insight and compromised self-evaluation). The clinician`s 
rating is not based on observation of functioning, only on information about the 
respondent’s feelings and experiences. For the control group we had no reasons to expect 
invalid information and only the self-report form was used. Both the self-report and 
9clinician rated form were used for the patient group to avoid the risk of underreports of 
amotivation. The two scales were highly intercorrelated (r=.6, p< .01).
We have previously shown that a shortened 12-item form of the clinical AES gave a 
better assessment of apathy than the full 18-item version in a first episode psychosis 
population [29]. The abridged version for both the clinical (AES-C-Apathy) and the self-
rated (AES-S-Apathy) was therefore used in the present study.  A score of 27 on both the
AES-S-Apathy and AES-C-Apathy was used as the cut off value for being clinically 
apathetic based on this score being two standard deviations (2 SD=8.6) above the mean 
sum scores (mean=18.0+4.3) of AES-S-Apathy for controls.
Diagnostic assessment
Diagnosis was assessed with Structural Clinical Interview for DSM-IV (SCID-I
interview) [36]. For the statistical analysis schizophrenia (N=45) schizophreniform-
(N=10) and schizoaffective disorder (N=2) were combined to “Schizophrenia spectrum”
group; major affective disorder with mood incongruent psychotic symptoms (N=14) and 
bipolar I disorder with mood incongruent psychotic symptoms (N=3) to the “Affective 
psychosis” group; and psychosis NOS (N=20), brief psychosis (N=7) and delusional 
disorder (N=2) were to the “Other psychosis” group.  
Assessment of drug use
The Alcohol and Drug use Scale, which separately measures drug and alcohol use the last 
six months [37], was used. The scores range from 1-5, with 1=no use, 2=use without 
impairment, 3=abuse, 4=dependence and 5=dependence with institutionalization.
Assessment of premorbid functioning
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Premorbid functioning was assessed with the Premorbid Adjustment Scale (PAS) [38].
The premorbid phase was defined as the time from birth until 6 months before the onset 
of psychosis. The premorbid phase is divided into four life periods: childhood (up to 11 
years), early adolescence (12–15 years), adolescence (16–18 years) and adulthood (19 
years and beyond). The scores range from 0–6, with 0 indicating the best level of 
functioning and 6 the worst. Several studies have confirmed two basic dimensions in the 
PAS: social (PAS-Social cluster) and academic (PAS-Academic cluster) [39,40]. We 
used the method described by Larsen et al. when calculating separate sum scores for 
PAS-Social cluster and PAS-Academic cluster functioning [39], and the method of Haahr 
et al [41] to calculate change scores for social (PAS-Social-change) and academic 
functioning (PAS-Academic-change).
Assessment of global functioning
The function score from the split version of the Global Assessment of Functioning scale
(GAF-F) was used to measure change in global functioning [42]. The split version has 
been found to discriminate adequately between symptoms and function [43] and has been 
used in other studies of first episode psychosis [44]. The GAF-F is a continuous scale 
ranging from 1–100, where 1 indicate the poorest- and 100 the highest functioning. The 
ratings are based on the assessor’s evaluation of the patient’s actual and functioning in
concrete areas such as work, social contacts and independent living. 
Procedures
All participants gave written informed consent to participate, and the Regional 
Committee approved the study for Medical Research Ethics and the Norwegian Data 
11
Inspectorate. The data file has received an Audit Certificate from the Center for Clinical 
research at Ullevål University Hospital.
The three investigators that carried out the assessments completed the common training 
and reliability program in the TOP study group. Training in the use of AES was done by 
scoring videos, supervised by two experienced clinicians that had previously used the 
scale with other patient groups [21]. The reliability testing of the AES was completed by
blind rating seven live interviews with randomly chosen patients from the study sample.
The SCID training was based on the UCLA training program [45], and supervised by 
UCLA. For DSM-IV diagnostics, mean overall kappa for the standard diagnosis of 
training videos was .77, and mean overall kappa for a randomly drawn subset of actual 
study patients was also  =.77 (95% CI=.60 - .94). Inter-rater reliability was acceptable 
with Intra Class Coefficient ((ICC)1.1) for the different subscales: PANSS positive 
subscale =.82 (95% CI=.66 - .94), PANSS negative subscale=.76 (95% CI=.58 - .93), 
PANSS general subscale=.73 (95% CI=.54 - .90), GAF-S=.86 (95% CI=.77 - .92) GAF-
F=.85 (95% CI=.76 - .92) and AES-C=.98 (95% CI=.92 - 99).
Statistical analyses
All analyses were done with SPSS version 16.0. Preliminary analyses were performed to 
examine the distribution of each variable. Logarithmic transformation was conducted 
when appropriate. Only duration of untreated psychosis required transformation to its 
natural logarithm, due to skewed data distribution. All tests were two tailed, with a preset 
level of significance of p=.05. Descriptive data are presented by either means and
standard deviation (SD), or median and range when appropriate. Bivariate correlations 
were calculated as Pearson product moment coefficients (r). Independent sample t-tests,
12
paired sample t-tests and one-way ANOVAs with post-hoc Scheffe’s test were used to 
analyze differences between groups.
Because several of the characteristics associated with measures of apathy and functioning 
(or both) were interdependent, the question of which patient characteristics that were 
independently related to apathy in the early treatment phase and to what degree apathy 
gave a specific contribution to the variation in functioning in first episode psychosis 
patients was explored through two separate multiple linear regression analyses. The 
independent variables were chosen for the regression analyses if they had a statistically 
significant correlation (p<.05) with the dependent variable in question (AES-C-Apathy
and GAF-F, respectively) (Table 2). For the purpose of a uniform and easy to read table 
the relationship between all dependent variables and independent variables are in this 
table presented through their correlation coefficients (also for dichotomous variables).
For research question three (which patient characteristics influence level of apathy), the 
independent variables were entered hierarchically in order of their life time appearance, 
with the first step representing background and premorbid variables (gender, age and 
premorbid adjustment), step two diagnosis and on the third step information about current 
status (drug or alcohol use, antipsychotic medication and symptoms). For research 
question four (to what degree apathy gave an independent contribution to level of 
functioning), symptoms were entered in order of their strength of their correlation with 
functioning in the bivariate analyses, with AES-C-Apathy on the last step after 
controlling for the influence of all other current symptoms. The final models were
checked for violation of assumptions and for the effects of outliers and influential 
13
observations. Analyses were done using the statistical package SPSS, version 15.0 for 
Windows. 
Results
Level of apathy in the patient- and healthy control group.
There was a statistically significant difference between the healthy control group and first 
episode psychosis patients in the mean AES-S-Apathy score (t=–9.7, df=162, p< .001)
(Table 1). Based on the pre-defined cut off for being clinically apathetic, 55 (53%) of the 
first episode psychosis patients were rated apathetic by the clinician (AES-C-Apathy) and 
56 (54%) rated them selves (AES-S-Apathy) as being apathetic, compared to only two
(3%) of the healthy control group.
Level of apathy in different diagnostic groups
There was a significant group difference in AES-C-Apathy score (F=4.16, df=2,100, p=
.02) between the diagnostic groups. Post hoc comparison (Scheffe) showed that this 
difference reached the level of statistical significance (p=.03) for the “Schizophrenia 
spectrum” (mean 28.3+6.4) and the “Other psychosis” group (mean 24.1+8.2). While the 
numerical score for the patients with “Affective psychosis” (mean 28.8+6.3) was nearly 
identical to that of patients with “Schizophrenia spectrum” it did not appear as 
statistically significantly different from the patients with “Other Psychosis” , probably 
due to a small N (i.e. a type II error cannot be ruled out).
Patient characteristics and relationship to apathy
Neither gender, current age, age at start of psychosis, duration of untreated psychosis, use 
of antipsychotic medication, use of alcohol or drugs or the level of PANSS-POS had 
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independent significant relationship with AES-C-Apathy (Table 2). In addition, PAS 
academic childhood cluster and PAS academic change did not have significant
association with AES-C-Apathy, and were thus not entered into the subsequent 
hierarchical regression analysis. Of the three diagnostic categories, only “Other 
psychosis” was statistically significantly correlated with AES-C-Apathy (negatively). Of
the different symptoms, only PANSS-DIS and PANSS-DEP were statistically 
significantly correlated (positively) (Table 2). These independent variables together with 
PAS social cluster childhood and PAS social change were thus entered into a hierarchical
regression analysis in three steps (Table 3). This model explained 18% of the variance in 
the AES-C-Apathy score (Table 3), with all steps having significant contributions. When 
the combined contribution of the different independent variables were studied together,
PAS social cluster childhood had the strongest significant contribution, together with 
PANSS-DIS and PAS social change, while the influence of “Other psychosis” diagnosis 
and PANSS-DEPR became non significant (Table 3). 
Apathy and functioning
GAF-F scores were statistically significantly negatively associated not only with AES-C-
Apathy, but also with PANSS-NEG, PANSS-POS and PANSS-DIS (Table 2). These 
variables were entered into the hierarchical regression analysis with GAF-F as the 
dependent (Table 4). Even when all other symptoms were controlled for, AES-C-Apathy 
had a significant contribution when entered at the last step (Table 4). This model 
explained 37% of the variance of the GAF-F scores (Table 4).
When the combined contribution of the different independent variables were studied 
together, only PANSS-POS and AES-C-Apathy had significant independent 
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contributions  while the contribution of PANSS-NEG and PANSS-DIS, became non-
significant (Table 4).
To study whether the aspects of different negative subsymptoms represented by the seven 
items comprised by the PANSS-NEG component had independent contributions, we
repeated the above analysis entering these items at the first step of the hierarchical
regression analysis (Table 5). The total explanatory power of this model was not changed 
compared to the original solution, and only the item PANSS-N 1, (flat affect) had a 
significant contribution together with PANSS-POS and AES-C-Apathy.
Discussion
The first important finding of this study is that apathy is a prevalent symptom in first 
episode psychosis patient. We found that more than 50 % of the participating patients 
were clinically apathetic, with the level of apathy was significantly higher in the patient 
group compared to the control group. The mean level of apathy in this study also appears
to be higher than levels found in left- or right sided acquired brain damage patients [21],
similar levels found in hypoxic brain damage patients [21], but lower than levels found 
in patients with Alzheimer`s dementia [27] (all measured by the AES). This underlines 
that the level of apathy in first episode psychosis patients is of a level associated with 
clinical consequences in other brain disorders [18,19] and thus warrants clinical attention
also in this patient group.
The second main finding is the clear and statistically significant contribution of apathy to 
functional loss in first episode psychosis patients, in line with a previous study of more 
chronic patients with schizophrenia who also found apathy as the best predictor of poor 
functioning [30]. The importance of apathy in relation to functioning must be seen in the 
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light of it’s definition as “lack of motivation and goal directed behavior” [27]. Goal 
directed behavior is one of the most important factors supporting development in a young 
person’s life [46] and the lack of motivation is thus a core feature of the negative 
symptoms [23].
The third main finding is the patient characteristics that have a significant influence on 
apathy. Poor premorbid social functioning and the presence of disorganized symptoms 
were significantly related to current level of apathy, while diagnosis, use of antipsychotic 
medication or depression was not. The clear associations with premorbid social 
functioning support the theory that apathy is a primary symptom linked to the 
neurodevelopmental origins of the disorders [47], and indicate that motivational loss 
influencing functioning may have been present even before the onset of psychotic 
symptoms. The relationship with disorganized symptoms adds further support to this 
theory as disorganization comprises different aspects of formal thought disorders often
regarded as more primary in nature compared to delusions and hallucinations [48]. The 
additional finding, that the level of AES-C-Apathy was independent of depression and 
use of antipsychotic medication is of interest, since the clinical evaluation of whether
treatable causes such as side-effects or depression lies behind lack of motivation is often 
difficult in clinical situations [9]. Since this is a cross sectional study, we cannot draw
any conclusions with certainty about their relative independence, but our findings are 
supported by studies of other brain disorders finding the same relative independence 
between apathy and depression [21,49,50].
The finding that the only other negative subsymptom (as measured by the PANSS) that 
contributed to poor functioning was flat affect (PANSS-NEG item N1) is of interest for 
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the further understanding of negative symptoms, since this is in line with the proposed 
subdivision of negative symptoms into the two domains of affective flattening on the one 
hand and apathy/avolition and anhedonia on the other [8,51].
Apathy is less diagnostically specific for schizophrenia spectrum disorders than 
hypothesized, as the level of apathy appears relatively similar in patients with first 
episode “Schizophrenia-spectrum” disorders and in patients with first episode “Affective 
psychosis” disorders (while the level in the “Other psychosis” group is significantly 
lower). Other studies have also pointed to similarities in the presence of negative 
symptoms in affective psychoses and schizophrenia [52,53]. Our finding thus supports 
the notion that studying similar symptoms across diagnostic boundaries may help us to 
better understand the underlying disease mechanisms, including easier linkage to 
underlying neurobiological substrates [54-56].
Finally, the measurement of apathy as a separate symptom rather than the broader 
concept of negative symptoms have several important clinical implications. Negative 
symptoms are often treatment refractive, is one of the main causes for functional 
disability and seriously impedes rehabilitation efforts.  However, the current behavioral 
description of negative symptoms as “social withdrawal” does not give aid on how we 
can improve patients’ functioning through focused interventions. The AES is a short and 
relatively simple rating scale that can help clinicians disentangle primary amotivation 
from treatable depression and medication side effects. Since rehabilitation is a goal 
directed process actively involving the patient, amotivation and lack of goal directed 
behavior is directly interfering with and obstructing this process. The possibility to assess 
the degree of motivational loss is thus a good starting point for rehabilitative efforts,
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since patients with high levels of apathy will need additional support and interventions. 
Awareness of the problem among staff can increase the proper use of remediation
techniques such as prompting and encouragement instead of critique. The use of 
motivational interviewing or other motivational techniques can be used in the treatment 
process and help patients with motivational problems focus on their goals and thus 
improve their engagement in the rehabilitation process. The above are in line with recent 
suggestions for more specific rehabilitative efforts [57-59] and a recent review on 
cognitive remediation naming motivation as the critical treatment target in order to 
optimize outcome [60]. Increased awareness of apathy in neuropsychiatric disorders has
increased the search for effective treatments [61]. Specific motivational and behavioral
approaches are taken into use such as engaging the patients through discussion groups, 
interactive education and homework assignments [61]. Studies also indicate that apathy 
to some extent can be alleviated by the use of dopamine agonists, but this type of 
treatment is problematic to use in psychotic disorders due to the risk of increasing
psychotic symptoms. In the longer run, more knowledge of the biological basis of apathy 
in schizophrenia may aid the development of more specific pharmacological treatments. 
Limitations
This is a cross sectional study and thus cannot conclude about the directions of the
relationships. First episode psychoses are rare, and hence number of participants is
limited. The functional measure is global, and thus cannot indicate if specific functional
areas are more affected by apathy than others are.
Conclusion
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Apathy is a common and clinically important symptom that is present at the beginning of
treatment in first episode psychosis patients, can be disentangled from depression and 
medication side effects and already at this point of time is significantly associated with  
functional loss. These findings have implications for services, as negative symptoms have 
been difficult to assess in clinical settings through existing evaluation methods. A high
level of apathy needs to be addressed in dealings with the patient, to find ways to 
strengthen motivation and set achievable goals. Staff and other caretakers must be 
informed, so that this symptom is not misinterpreted as laziness or met with critique, but 
instead handled in ways that increase motivation.
Acknowledgments
References
1. Mueser KT, McGurk SR: Schizophrenia. Lancet 363:2063-2072, 2004.
2. Olesen J, Baker MG, Freund T, et al: Consensus document on European brain
research. Journal of Neurology, Neurosurgery and Psychiatry 77 Suppl 1:i1-49,
2006.
3. McGlashan TH, Fenton WS: The positive-negative distinction in schizophrenia. 
Review of natural history validators. Archives of General Psychiatry 49:63-72,
1992.
20
4. Herbener ES, Harrow M: Are negative symptoms associated with functioning 
deficits in both schizophrenia and nonschizophrenia patients? A 10-year 
longitudinal analysis. Schizophrenia Bulletin 30:813-825, 2004.
5. McGurk SR, Moriarty PJ, Harvey PD, et al: The longitudinal relationship of clinical 
symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia. 
Schizophrenia Research 42:47-55, 2000.
6. Wyatt RJ, Henter I: Rationale for the study of early intervention. Schizophrenia 
Research 51:69-76, 2001.
7. Whitty P, Clarke M, McTigue O, et al: Predictors of outcome in first-episode 
schizophrenia over the first 4 years of illness. Psychological Medicine 38:1141-
1146, 2008.
8. Kirkpatrick B, Fenton WS, Carpenter WT, Jr., et al: The NIMH-MATRICS 
consensus statement on negative symptoms. Schizophrenia Bulletin 32:214-219,
2006.
9. Miller AL, Mahurin RK, Velligan DI, et al: Negative symptoms of schizophrenia: 
where do we go from here? Biological Psychiatry 37:691-693, 1995.
10. Erhart SM, Marder SR, Carpenter WT: Treatment of schizophrenia negative 
symptoms: future prospects. Schizophrenia Bulletin 32:234-237, 2006.
11. Blanchard JJ, Cohen AS: The structure of negative symptoms within schizophrenia: 
implications for assessment. Schizophrenia Bulletin 32:238-245, 2006.
21
12. Sass H: The historical evolution of the concept of negative symptoms in 
schizophrenia. Br J Psychiatry Suppl26-31, 1989.
13. Crow TJ: Positive and negative schizophrenic symptoms and the role of dopamine. 
Br J Psychiatry 137:383-386, 1980.
14. Andreasen NC: Negative symptoms in schizophrenia. Definition and reliability. 
Archives of General Psychiatry 39:784-788, 1982.
15. Marin RS: Apathy: a neuropsychiatric syndrome. Journal of Neuropsychiatry and 
Clinical Neurosciences 3:243-254, 1991.
16. Stuss D.T, Knight R.T: Principles of Frontal Lobe Function. New York, Oxford 
University Press, 2002.
17. Tekin S, Cummings JL: Frontal-subcortical neuronal circuits and clinical 
neuropsychiatry: an update. Journal of Psychosomatic Research 53:647-654, 2002.
18. Landes AM, Sperry SD, Strauss ME, et al: Apathy in Alzheimer's disease. Journal 
of the American Geriatrics Society 49:1700-1707, 2001.
19. Pluck GC, Brown RG: Apathy in Parkinson's disease. Journal of Neurology, 
Neurosurgery and Psychiatry 73:636-642, 2002.
20. Paulsen JS, Ready RE, Hamilton JM, et al: Neuropsychiatric aspects of 
Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry 71:310-
314, 2001.
22
21. Andersson S, Krogstad JM, Finset A: Apathy and depressed mood in aquired brain 
damage: relationship to lesion localization and psychophysiological reaction. 
Psychological Medicine 29:447-56, 1999.
22. Kraepelin E: Dementia Praecox and Paraphrenia. Huntington, New York, Robert E. 
Krieger Publishing Co Inc., 1971.
23. Brown RG, Pluck G: Negative symptoms: the 'pathology' of motivation and goal-
directed behaviour. Trends in Neurosciences 23:412-417, 2000.
24. Foussias G, Remington G: Negative Symptoms in Schizophrenia: Avolition and 
Occam's Razor. Schizophrenia Bulletin Jul 21 [Epub ahead of print], 2008.
25. Barch DM: Emotion, Motivation, and Reward Processing in Schizophrenia 
Spectrum Disorders: What We Know and Where We Need to Go. Schizophrenia 
Bulletin 816-818, 2008.
26. Welham J, Stedman T, Clair A: Choosing negative symptom instruments: issues of 
representation and redundancy. Psychiatry Research 87:47-56, 1999.
27. Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy 
Evaluation Scale. Psychiatry Research 38:143-162, 1991.
28. Starkstein SE, Petracca G, Chemerinski E, et al: Syndromic validity of apathy in 
Alzheimer's disease. American Journal of Psychiatry 158:872-877, 2001.
29. Faerden A, Nesvag R, Barrett EA, et al: Assessing apathy: the use of the Apathy 
Evaluation Scale in first episode psychosis. European Psychiatry 23:33-39, 2008.
23
30. Kiang M, Christensen BK, Remington G, et al: Apathy in schizophrenia: clinical 
correlates and association with functional outcome. Schizophrenia Research 63:79-
88, 2001.
31. The Frontal Lobes and Neuropsychiatric Illness. Washington, DC 20005, American 
Psychiatric Publishing Inc., 2008.
32. Spitzer RL, Williams JB, Kroenke K, et al: Utility of a new procedure for 
diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA 
272:1749-1756, 1994.
33. Kay SR, Fiszbein A OL: The positive and negative syndrome Scale (PANSS) for 
schizophrenia. Schizophrenia Bulletin 16:261-276, 1987.
34. Toomey R, Kremen WS, Simpson JC, et al: Revisiting the factor structure for 
positive and negative symptoms: evidence from a large heterogeneous group of 
psychiatric patients. American Journal of Psychiatry 154:371-377, 1997.
35. Emsley R, Rabinowitz J, Torreman M: The factor structure for the Positive and 
Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophrenia 
Research 61:47-57, 2003.
36. American Psychiatric Association: Diagnostic and Statistical Manual of Mental 
Disorders DSM IV. Washington DC, American Psychiatric Association, 1994.
37. Mueser K, Noordsy D, Drake R, et al: Integrated Treatement for Dual Disorders. 
New York, The Guilford Press, 2003.
24
38. Cannon-Spoor HE, Potkin SG, Wyatt RJ: Measurement of premorbid adjustment in 
chronic schizophrenia. Schizophrenia Bulletin 8:470-484, 1982.
39. Larsen TK, Friis S, Haahr U, et al: Premorbid adjustment in first-episode non-
affective psychosis: distinct patterns of pre-onset course. British Journal of 
Psychiatry 185:108-115, 2004.
40. MacBeth A, Gumley A: Premorbid adjustment, symptom development and quality 
of life in first episode psychosis: a systematic review and critical reappraisal. Acta 
Psychiatr Scand 117:85-99, 2008.
41. Haahr U, Friis S, Larsen TK, et al: First-episode psychosis: diagnostic stability over 
one and two years. Psychopathology 41:322-329, 2008.
42. Pedersen G, Hagtvet KA, Karterud S: Generalizability studies of the Global 
Assessment of Functioning-Split version. Comprehensive Psychiatry 48:88-94,
2007.
43. Jones SH, Thornicroft G, Coffey M, et al: A brief mental health outcome scale-
reliability and validity of the Global Assessment of Functioning (GAF). British 
Journal of Psychiatry 166:654-659, 1995.
44. Melle I, Larsen TK, Haahr U, et al: Prevention of negative symptom 
psychopathologies in first-episode schizophrenia: two-year effects of reducing the 
duration of untreated psychosis. Archives of General Psychiatry 65:634-640, 2008.
25
45. Ventura J, Liberman RP, Green MF, et al: Training and quality assurance with the 
Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Research 79:163-
173, 1998.
46. Pintrich PR, Schunk DH: Motivation in Education. Theory, research and 
applications. Upper Saddle River, New Jersey,Colombus, USA, Merrill Prenctice 
Hall, 2002.
47. Hollis C: Developmental precursors of child- and adolescent-onset schizophrenia 
and affective psychoses: diagnostic specificity and continuity with symptom 
dimensions. British Journal of Psychiatry 182:37-44, 2003.
48. Basso MR, Nasrallah HA, Olson SC, et al: Neuropsychological correlates of
negative, disorganized and psychotic symptoms in schizophrenia. Schizophrenia 
Research 31:99-111, 1998.
49. Starkstein SE, Ingram L, Garau ML, et al: On the overlap between apathy and 
depression in dementia. Journal of Neurology, Neurosurgery and Psychiatry 
76:1070-1074, 2005.
50. Kirsch-Darrow L, Fernandez HH, Marsiske M, et al: Dissociating apathy and 
depression in Parkinson disease. Neurology 67:33-38, 2006.
51. Blanchard JJ, Cohen AS: The Structure of Negative Symptoms Within 
Schizophrenia: Implications for Assessment. Schizophrenia Bulletin 2005.
26
52. Galynker II, Cai J, Ongseng F, et al: Hypofrontality and negative symptoms in 
major depressive disorder. Journal of Nuclear Biology and Medicine 39:608-612,
1998.
53. Lavretsky H, Ballmaier M, Pham D, et al: Neuroanatomical characteristics of 
geriatric apathy and depression: a magnetic resonance imaging study. American 
Journal of Geriatric Psychiatry 15:386-394, 2007.
54. Roth RM, Flashman LA, Saykin AJ, et al: Apathy in schizophrenia: reduced frontal 
lobe volume and neuropsychological deficits. American Journal of Psychiatry 
161:157-159, 2004.
55. Apostolova LG, Akopyan GG, Partiali N, et al: Structural correlates of apathy in 
Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 24:91-97, 2007.
56. Andersson S, Bergedalen AM: Cognitive correlates of apathy in traumatic brain 
injury. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 15:184-191,
2002.
57. Kopelowicz A, Liberman RP: Integrating treatment with rehabilitation for persons 
with major mental illnesses. Psychiatric Services 54:1491-1498, 2003.
58. Velligan DI, Mueller J, Wang M, et al: Use of environmental supports among 
patients with schizophrenia. Psychiatric Services 57:219-224, 2006.
59. Whitehorn D, Lazier L, Kopala L: Psychosocial rehabilitation early after the onset 
of psychosis. Psychiatric Services 49:1135-7, 1147, 1998.
27
60. Velligan DI, Kern RS, Gold JM: Cognitive rehabilitation for schizophrenia and the 
putative role of motivation and expectancies. Schizophrenia Bulletin 32:474-485,
2006.
61. Roth RM, Flashman LA, McAllister TW: Apathy and its treatment. Curr Treat 
Options Neurol 9:363-370, 2007.
Table 1 
Demographic and clinical data for 103 first episode psychosis patients and 62 from the
healthy control group
Patients
(N = 103)
Healthy Control
group (N = 62)
N or mean % N or mean %
Age (mean + SD years) 27.3 +7.7 32.0 +9.3
Male gender                 60 58 28 45
Education (mean + SD years) 13.0 +2.7 13.9 +1.9
Age at onset of illness (mean + SD years) 24.3 +7.6
Duration of untreated psychosis in weeks (median, range) 35 ( 1-1040)
Antipsychotic medication 81 79
Hospitalized for psychosis 69 67
Alcohol misuse or dependencea 11 12
Drug misuse or dependencea 22 21
Premorbid Functionb
PAS - Social cluster level childhood 1.4 +1.6
PAS – Social-change .1 +1.9
PAS - Academic cluster level childhood 1.6 +1.2
PAS – Academic-change 0.7 +1.4
Diagnosis
“Schizophrenia spectrum” 57 55
“Affective psychosis” 17 17
“Other Psychosis”              29 28
Symptoms and function
AES-C-Apathyc 27.2 +7.1
AES-S-Apathyc 27.7 +7.2 18.0 +4.3
PANSS - Total scored                          60.9 +14.5
PANSS - POS (P1,P3,P5,P6,G9,G12)d                   14.7 +5.2
PANSS - DIS  (P2,N5,N7,G5,G10,G11,G15)d 11.1 +3.6
PANSS - NEG (N1,N2,N3,N4,N6,G7,G13,G16) d                 16.8 +6.0
PANSS - DEP (G1,G2,G3,G4,G6)d 12.4 +4.1
PANSS - EXC (P4,P7,G8,G14)d              5.6 +1.9
GAF- Symptomsf 41.9 +12.7
GAF- Functioningf             45.5 +12.7
Abbreviations:
a Alcohol and drug use scale. Scores range from 1-5 with higher scores indicating more severe dependence. A score >3 indicate misuse
or dependence 
b PAS Premorbid Adjustment Scale. Possible scores range from 0, best functioning, to 6, worst functioning
c AES-C-Apathy Apathy Evaluation Scale clinician rated abridged version; Possible scores range from 12 to 48, with higher scores 
indicating more apathy
dAES-S-Apathy Apathy Evaluation Scale self assessed bridged version; Possible scores range from 12 to 48, with higher scores 
indicating more apathy
d PANSS Positive and Negative Syndrome Scale. Possible scores range from 30-210 for the PANSS-total, for PANSS-POS from 
6- 42, PANSS-DIS from 7- 49; PANSS-NEG from 7- 49, PANSS-DEPR from 5 - 35, PANSS-EXC 4 to 20. For all higher score
indicating more symptoms 
f GAF Global Assessment of Functioning Scale, split version Possible scores range from 1-100, with higher scores indicating 
less symptoms or better functioning
Table 2
Pearson correlations between clinical variables and 
AES-C-Apathy and GAF-F
AES-C-Apathy GAF-F
Gender -.07
Age -.03
Age at start psychosis -.05
Duration of untreated psychosis .16
Use of antipsychotic medicine .01
Alcohol use scale .04
Drug use scale .16
”Schizophrenia spectrum” .17
“Affective psychosis” .10
“Other psychosis ” -.28**
AES-C-Apathy -.44**
PANSS Five Subscores
PANSS - POS .19 -.47**
PANSS - DIS .28** -.47**
PANSS - NEG .58** -.50**
PANSS - DEP .23* -.17
PANSS - EXC .02 -.10
Abbreviations
AES-C-Apathy Apathy Evaluation Scale, clinician-rated and abridged version 
GAF-F Global Assessment of Functioning Scale, split version  functioning  
DUP Duration of untreated psychosis
AES-S-Apathy Apathy Evaluation Scale, self assessed abridged version 
PANSS Positive and  Negative Syndrome Scale
*p<0.05 
**p<0.01
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Abstract
Background: The underlying nature of negative symptoms in psychosis is poorly understood.
Investigation of the relationship between the different negative subsymptoms and neurocognition
is one approach to understand more of the underlying nature. Apathy, one of the subsymptoms, is
also a common symptom in other brain disorders. Its association with neurocognition, in particular
executive functioning, is well documented in other brain disorders, but only studied in one former
study of chronic patients with schizophrenia. This study investigates the association between apathy
and neurocognitive functioning in patients with first episode psychosis (FEP), with the hypothesis
that apathy is more associated with tests representing executive function than tests representing
other neurocognitive domains.
Methods: Seventy-one FEP patients were assessed with an extensive neuropsychological test
battery. Level of apathy was assessed with the abridged Apathy Evaluation Scale (AES-C-Apathy).
Results: AES-C-Apathy was only significantly associated with tests from the executive domain
[Semantic fluency (r = .37, p < .01), Phonetic fluency (r = .25, p < .05)] and working memory [Letter
Number Span (r = .26; p =< .05)]; the first two representing the initiation part of executive
function. Confounding variables such as co-occuring depression, positive symptoms or use of
antipsychotic medication did not significantly influence the results.
Conclusion: We replicated in FEP patients the relationship between apathy and executive
functioning reported in another study for chronic patients with schizophrenia. We also found
apathy in FEP to have the same relationship to executive functioning, as assessed with the Verbal
fluency tests, as that reported in patients with other brain disorders, pointing to a common
underlying nature of this symptom across disorders.
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Background
Negative symptoms are common in patients with psycho-
sis, but the underlying mechanisms are still poorly under-
stood [1]. Neurocognitive deficits are also common in
schizophrenia spectrum disorders, and are thought to be
more closely linked to the biological underpinnings of the
disorder than clinical symptoms [2]. As negative symp-
toms is repeatedly shown to have a consistent relationship
with neurocognitive deficits [3-6], a further exploration of
their relationship may aid the search for the mechanisms
behind negative symptoms. A recent review by Harvey et
al suggested four models as potential explanations for
their association [7]: 1) the two categories of symptoms
represent the same identical features or alternate manifes-
tations of the same basic underlying process, or 2) the two
features of the illness are separable but share similar
underlying etiological factors, or 3) the two are of sepa-
rate, but related etiologies, or 4) the two dimensions are
distinct from each other and with separate etiology. The
review concluded by inviting innovations in the assess-
ment of negative symptoms to come closer to an under-
standing of negative symptoms and other aspects of
psychosis [7].
One problem in studies of negative symptoms is the het-
erogeneity of patient samples examined, with an admix-
ture of chronic samples marked by treatment failures,
institutionalization, hopelessness and subsequent social
consequences that are difficult to distinguish from pri-
mary negative symptoms based solely on behavioral
observations. Another problem is the diverse nature of the
negative symptoms per se, as it includes several subsymp-
toms (apathy or avolition, anhedonia, alogia, asociality,
flat affect and inattention) that might have different etiol-
ogies. Based on the recognition of this diversity, the
"NIMH-MATRICS consensus statement on negative symp-
toms" has suggested that studies specific to the nature of
these negative subsymptoms is one way to move forward
[1]. So far, very few studies on the association between
negative symptoms and neurocognitive function have
included analysis on the subsymptom level. We have thus
found only four studies addressing the specific relation-
ship between any of the negative subsymptoms and neu-
rocognitive function [8-11]; the subsymptoms studied
being alogia [8,10] flat affect [8,11] and apathy [9].
Apathy, defined as lack of motivation or goal directed
behavior [12], has lately been targeted as an important
negative subsymptom that need further study [13-15].
However, the only study concerned with the association
between apathy and neurocognition in psychosis is based
on a small sample of chronic patients with schizophrenia
and a narrow test battery [9]. Here, a high level of apathy
was associated with lower performance IQ scores and
poor performance on tests assessing executive function
and visual- and verbal memory. The authors called for
new studies in order to generalize their findings, due to
the small sample size and lack of a comprehensive neu-
ropsychological test battery. Studying patients with their
first episode of psychosis (FEP) is of particular interest,
since the negative symptoms in such a sample cannot be
secondary to chronic effects, treatment failures or social
deprivation.
Apathy is considered a symptom arising from the prefron-
tal cortex [16] or from dysfunction in the frontal-subcor-
tical circuits [17]. It's relationship to neurocognitive
function has been extensively studied in other brain disor-
ders, such as Alzheimer – (AD) [18], Parkinson – (PD)
[19] and Huntington disease (HD) [20] in addition to
traumatic brain injury (TBI) [21]. Common to studies of
all the above disorders is the finding of a consistent rela-
tionship between high levels of apathy and poorer per-
formance on tests representing executive function [19-
24]. In addition, significant associations are found to
other neurocognitive domains, especially working mem-
ory [19,24], psychomotor speed [21], attention [20] and
episodic memory [20,21], but for these domains the pat-
tern of association is less systematic.
The aim of the present study is to improve our under-
standing of apathy in FEP patients. Consequently, we
wish to investigate the association between apathy and
neurocognitive function. First, we hypothesize that also in
FEP patients the degree of apathy will be significantly
related to tests representing executive function, and less
with tests representing other neurocognitive domains.
Secondly, we hypothesize that this relationship is not
influenced by confounding variables, such as depression,
use of antipsychotic medication or positive symptoms,
supporting the notion of a linked etiology between the
two areas.
Methods
2.1 Participants
The present study includes 71 FEP patients with a fluent
understanding of Norwegian, recruited between July 2004
and end of June 2006. They all took part in both the clin-
ical and the neuropsychological assessment in the ongo-
ing Thematically Organized Psychosis (TOP) research
study in Oslo, Norway. All patients were assessed in a sta-
ble phase. The neurocognitive testing was done in as close
connection to the clinical assessment as possible, within
one to eight weeks. Inclusion criteria were: Age between
18 and 65 years, with a first episode of psychosis and a
DSM-IV diagnosis of either schizophrenia, schizophreni-
form disorder, schizoaffective disorder (constituting
schizophrenia spectrum disorders); psychosis NOS, delu-
sional disorder, brief psychosis (constituting other psy-
chotic disorders), or affective disorder with mood
BMC Psychiatry 2009, 9:1 http://www.biomedcentral.com/1471-244X/9/1
Page 3 of 8
(page number not for citation purposes)
incongruent psychotic symptoms and bipolar disorder
(constituting affective psychotic disorders). Patients were
eligible for inclusion up to 52 weeks following the start of
the first adequate treatment. Being psychotic was defined
as having a rating of 4 or more on anyone of the PANSS
items P1, P3, P5, P6 or G9. Fifty seven (80.3%) of all used
antipsychotic medication (AP); 51 on monotheraphy and
six on two AP's. Of these 57, three were using first genera-
tion AP [Zuclopentixol (N = 2); Perphenazine (N = 1)]
and the rest second generation AP [Olanzapine (N = 28);
Risperidone (N = 9); Ziprazidone (N = 9); Quetiapine (N
= 7), Aripriprazole (N = 5) and Amisulpride (N 01)]. The
average Defined Daily Dosage of Antipsychotics (DDD-
AP) assignment according to the World Health Organiza-
tion was 1.08 (SD .61) [25]. Table 1 shows the demo-
graphics, diagnostic groups and symptoms of the 71
participants.
2.2 Assessment
2.2.1 Measures
Assessment of apathy
Apathy was assessed by the clinical version of the Apathy
Evaluation scale (AES-C), an 18-item Likert scale ranging
from 0–4 (0 = not at all and 4 = very much) [26]. The scale
is based on Marin's definition of apathy as " diminished
motivation and goal directed behavior, not attributed to
diminished level of consciousness, general cognitive
impairment or emotional distress" [26]. Examples of the
questions are: "Are you interested in things?", "Is it impor-
tant for you to get things done during the day?" and "Do
you feel motivated?" The scale has been used across differ-
ent medical disciplines. We have previously shown that a
shortened 12-item AES-C scale (AES-C-Apathy) was a bet-
ter assessor of apathy than the full version in a population
with a FEP [27]. This abridged version was used in all the
analyses in the present study.
Assessment of other symptoms and diagnosis
Symptoms were assessed by the Structural Clinical Inter-
view of the PANSS (SCI-PANSS) [28]. Depression was
assessed with the Calgary Depression Scale for schizo-
phrenia (CDSS) [29]. Diagnostic assessment was carried
out with the Structural Clinical Interview for DSM-IV
(SCID-I interview) [30].
2.3 Neuropsychological assessments
A comprehensive neuropsychological test battery was
administrated to all participants by psychologists or psy-
chology students trained in clinical neuropsychology. The
tests cover domains shown to be sensitive to the neuro-
cognitive dysfunction of psychosis [31,32]: motor func-
tion (Grooved Pegboard) [33], psychomotor speed (Digit
Symbol from WAIS-III) [34], attention (Digit Span for-
wards from WAIS-III) [34], working memory (Letter
Number Span from WAIS-III) [34], verbal learning (Cali-
fornia Verbal Learning Test; CVLT-II) [35], visual learning
(Rey-Oesterrieth Complex Figure Test) [36] and executive
function. For the executive function domain several tests
from the Delis-Kaplan Executive Function System (D-
KEFS) [37] were included in order to enable the investiga-
tion of the association of apathy with three different
aspects of executive function; initiation, set shifting and
inhibition. Initiation was assessed with Semantic fluency
and Phonetic fluency (from the Verbal Fluency test) [37].
Table 1: Sociodemographic and clinical variables for 71 FEP 
patients
Mean SD
Age (years) 27.4 8.1
Education (years) 12.5 2.7
DUP (weeks) median/range 30 1–1040
GAF symptoms 42.8 14.0
GAF function 46.1 14.4
AES-C-Apathy 27.2 7.1
PANSS total score 60.5 15.1
PANSS positive 14.4 5.1
PANSS negative 14.7 5.8
PANSS general 31.3 7.4
CDSS 6.4 4.5
N %
Male gender 37 52%
Living alone 63 89%
Diagnosis
Schizophrenia spectrum group 36 51%
Affective psychosis gorup 15 21%
Other psychosis group 20 28%
Abbreviations: DUP, duration of untreated psychosis; GAF, Global 
Assessment of Functioning Scale; PANSS, Positive and Negative 
Syndrome Scale; CDSS, Calgary Depression Scale for Schizophrenia; 
Schizophrenia spectrum group [schizophrenia (N = 30), 
schizophreniform (N = 6)]; Affective psychosis group [major 
depressive psychosis with mood incongruent psychosis (N = 12), 
Bipolar (N = 3)]; Other psychosis group [psychosis NOS (N = 13, 
brief psychosis (N = 6), delusional disorder (N = 1)]
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Set shifting was assessed with Category Switching (also
from the Verbal Fluency test) [37], whereas inhibition was
measured with the third trial on the Color-Word Interfer-
ence test (the "Stroop" condition) [37]. Premorbid IQ was
assessed with a Norwegian Research version of the
National Adult Reading Test (NART) [38]; and current IQ
with Wechsler Abbreviated Scale of Intelligence (WASI;)
[39]. All participants showed adequate neuropsychologi-
cal test effort indicated by two errors or less on the forced
recognition trial of the CVLT-II. Table 2 gives the test
results of the 71 patients.
2.4 Procedures
All participants gave written informed consent to partici-
pate, and the study was approved by the Regional Com-
mittee for Medical Research Ethics and the Norwegian
Data Inspectorate. The data file has received an Audit Cer-
tificate from the Center for Clinical research at Ullevål
University Hospital.
The three investigators who did all the clinical assess-
ments in the current study completed the common train-
ing and reliability program of the TOP study. Training in
the AES-C was done by scoring videos, supervised by two
experienced clinicians who had previously used the scale
with other patient groups [40], and reliability testing of
the AES-C was completed by seven live interviews with
random study patients. The SCID training was based on
the UCLA training program [41], and supervised by
UCLA. For DSM-IV diagnostics, mean overall kappa for
the standard diagnosis of training videos was 0.77, and
mean overall kappa for a randomly drawn subset of actual
study patients was also 0.77 (95% CI 0.60–0.94). Inter-
rater reliability (Intra Class Coefficient (ICC) 1.1) for the
different psychometric scales were: PANSS positive sub-
scale 0.82 (95% CI 0.66–0.94) PANSS negative subscale
0.76 (95% CI 0.58–0.93), PANSS general subscale 0.73
(95% CI 0.54–0.90), GAF-S 0.86 (95% CI 0.77–0.92),
GAF-F 0.85 (95% CI 0.76–0.92) and AES-C 0.98 (95% CI
0.92–0.99).
2.5 Analyses
2.5.1 Data and statistical analyses
Analyses were performed with the statistical package SPSS,
version 15.0 for Windows. A preliminary analysis was per-
formed to examine the distribution of each variable. One
patient was excluded because of being an extreme outlier
on the Semantic fluency tests with 4 SD above the group
mean (outlier score = 75; group mean = 40.1, SD = 8.6)
influencing the results to such a degree that assumptions
of homogeneity were violated. All tests were two-tailed,
with a preset significance level of 0.05. Bonferroni correc-
tions were applied in analyses where more than one test
represented a neurocognitive domain, as noted in Table 3.
Descriptive data are presented by either means or stand-
ard deviation (SD), or by median and range. Independent
Student t-tests were used to analyze differences between
groups. Associations between AES-C-Apathy and neu-
ropsychological tests were investigated with Pearson
Table 2: Neuropsychological test results for 71 FEP patients
Test Mean SD
IQ
NART (N = 66) 14.4 7.3
WASI (N = 71) 105.2 13.7
Motor function
Grooved Pegboard (N = 70) 110.2 26.5
Psychomotor speed
Digit Symbol (N = 71) 63.5 14.4
Attention
Digit Span forward (N = 71) 5.8 1.1
Verbal memory
CVLT-II (N = 71) 53.0 10.5
Visual memory
ROCF long term memory (N = 65) 19.5 6.7
Working memory
Letter Number Span (N = 65) 9.7 2.5
Executive function
Initiation
Phonetic fluency (N = 71) 38.4 11.9
Semantic fluency (N = 71) 39.6 7.6
Set shifting
Category switching (N = 71) 12.4 2.7
Inhibition
Color-Word Interference (N = 71) 60.0 21.0
Abbreviations: NART, National Adult Reading test; WASI, Wechsler 
Abbreviated Scale of Intelligence; CVLT-II, California Verbal Learning 
Test II; ROCF, Rey-Osterrieth Complex Figure Test.
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Table 3: Correlation between neuropsychological tests, AES-C-Apathy and possible confounding variables
Test (N) AES-C-Apathy CDSS PANSS Positive DDD-AP
r r r r
IQ
Premorbid: NART .11 <.01 .25* .11
Current: WASI -.15 -.02 -.11 -.23
Motor function
Grooved Pegboard .09 -.02 .14 .18
Psychomotor speed
Digit symbol -.17 -.04 -.11 -.15
Attention
Digit span forwards -.13 .02 .04 -.14
Verbal memory
CVLT-II -.15 .05 -.15 -.13
Visual memory
ROCF long term memory -.16 -.05 -.10 -.21
Working memory
Letter Number Span -.26* -.07 -.13 -.13
Executive function
Initiation
Phonetic fluencya -.25* -.08 < -.01 -.17
Semantic fluencya -.37** -.05 -.04 -.11
Set shifting
Category switching -.18 .06 .02 -.24*
Inhibition
Color-Word Interference .23 .10 .25* .10
r = Pearson product moment correlation; *p <.05; a Bonferroni corrected (0.05/2 = .03) * = p  .03; ** = p  .01
Abbreviations: NART, National Adult Reading Test; WASI, Wechsler Abbreviated Scale of Intelligence; CVLT-II, California Verbal Learning Test II; 
ROCF, Rey-Osterrieth Complex Figure Test; AES-C-Apathy, abridged Apathy Evaluation Scale; CDSS, Calgary Depression Scale for Schizophrenia; 
PANSS, Positive and Negative Syndrome Scale; DDD-AP, indicates defined daily dose according to the World Health Organization of Antipsychotic 
medication
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product moment correlation analysis (r) and degree of
influence by univariate regression analysis.
Since apathy, negative symptoms and neurocognitive
function have been found to be under influence from sec-
ondary sources, we took steps to control for this. Depres-
sion has been tested as a possible confounding variable
for apathy in different studies in other medical disciplines
[18,21], in addition positive symptoms and current use of
antipsychotic medication has in some studies been found
to influence either negative symptoms or neurocognitive
function [42]. The association between these three varia-
bles and neurocognition were firstly examined in a corre-
lation analysis followed by a hierarchical multiple
regression analysis with the neurocognitive test results as
the dependent. The possible confounders and AES-C-Apa-
thy were the independent variables, with AES-C-Apathy
entered in the last step.
Results
3.1 The relationship between apathy, neuropsychological 
test performance and confounding variables
Three of the neuropsychological tests in the comprehen-
sive TOP battery showed a statistically significant inverse
association to AES-C-Apathy (Table 3). Out of these two
(Semantic- and Phonetic fluency part of the Verbal Flu-
ency tests) represented the initiation part of executive
function, and the third (Letter Number Span) represented
working memory. AES-C-Apathy was most strongly corre-
lated with the Semantic fluency test (r = .37, p = .002),
explaining 12% of its variance. For the two other tests
(Phonetic fluency and Letter Number Span) the relation-
ship to AES-C-Apathy was statistically significant, but of a
smaller magnitude (r = .25, r = .26). AES-C-Apathy was
neither significantly associated with any other tests, nor
premorbid or current IQ.
There were no statistically significant differences in test
performance for any neuropsychological tests (p value
between .18 – .99) or in level of apathy (F = .16; p = .69)
between the unmedicated patients (N = 14) and patients
using antipsychotic medication (N = 57). None of the
possible confounding variables (DDD-AP, PANSS posi-
tive symptoms or CDSS) had any significant correlations
with the three neuropsychological tests that were statisti-
cally significantly associated with AES-C-Apathy (Table
3). This lack of influence was confirmed in a hierarchical
regression analysis with Semantic-, Phonetic fluency and
Letter Number Span as dependent variables. Here only
AES-C-Apathy had a statistically significant contribution,
even when entered in the last step (Table 4). The entry of
the possible confounding variables did not change the
influence AES-C-Apathy had on the neuropsychological
tests in the univariate regression analysis (Table 4).
Discussion
The main result of the present study is the replicated find-
ing of a significant relationship between apathy and exec-
utive function in psychotic disorders, as found previously
in one study of patients with chronic schizophrenia [9].
The two findings are corresponding even if the two studies
applied different measures both for apathy and executive
Table 4: Univariate and hierarchial multivariate regression analysis with neuropsychological tests as dependent and AES-C-Apathy and 
possible counfounders as independent variables
Dependent Dependent Dependent
Letter Number Span Phonetic fluency Semantic fluency
Independent variables R2adj  t p R2 adj  t p R2 adj  t p
Univariate
AES-C-Apathy .05 -.26 -2.2 .04 .05 -.25 -2.2 .03 .12 -.37 -3.3 <.01
Hierarchial
DDD-AP .01 -.13 -1.1 .30 .02 -.19 -1.6 .12 .00 -.12 -1.0 .31
PANSS positive .01 -.06 -.5 .62 .01 .07 .6 .56 -.01 .04 .3 .75
CDSS -.09 .05 .3 .72 -.02 .05 .4 .72 -.03 .15 1.2 .25
AES-C-Apathy .04 -.27 -2.0 .05 .05 -.29 -2.2 .03 .12 -.44 -3.5 <.01
adj = adjusted; DDD-AP, indicates defined daily dose according to the World Health Organization of antipsychotic medication PANSS, Positive and 
Negative syndrome Scale; CDSS, Calcary Depression Scale for Schizophrenia; AES-C-Apathy, abridged Apathy Evaluation Scale
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function, indicating a robust relationship. In addition, in
both studies the relationship was not influenced by cur-
rent level of depression. This supports the view that the
presence of apathy and deficits in executive functioning
are related in psychotic disorders, and that the relation-
ship is not due to definitional issues since different scales
and tests were used.
Additionally, this finding is in line with findings of an
association between apathy and the specific executive
functioning test of verbal fluency in several other brain
disorders [18-20,22]. Two of these studies used the AES in
assessing apathy [19,22], eliminating the challenge of
comparing results between different scales.
This finding of a consistent relationship between apathy
and tests of executive function across different brain disor-
ders and across different levels of chronicity is supported
by several studies that implicate prefrontal areas and fron-
tal-subcortical circuitry involving the anterior cingular
gyrus in both apathy and executive function [43-47].
In our opinion, our findings thus support the idea of a
common or linked etiology between these negative symp-
toms and neurocognitive deficits as put forward in Harvey
et al's model 2 and 3 [7]. This is in opposition to Harvey's
own conclusions, that suggests that the two have different
etiologies based on a lack of published studies showing
significant relationships. In addition, our findings might
imply that there are specific mechanisms behind the dif-
ferent negative subsymptoms. This is supported by a
recent study finding that verbal memory was the only neu-
ropsychological test to differentiate between those with
and without flat affect, making the authors' suggest that
this could reflect a unique neural substrate for this nega-
tive subsymptom [11].
We did not, as Roth et al, find associations between high
levels of apathy and reduced IQ and memory, associations
with apathy that are also found in other disorders. This
could be due to the differences between the studies such
as assessment of apathy, FEP patients being less chroni-
cally ill and diagnostically more diverse. But in order to
understand more of the different negative subsymptoms,
these associations should also be further studied.
The strength of our study is the use of a specific and vali-
dated assessment for the negative subsymptom of apathy
together with a comprehensive neuropsychological test
battery with tests for several different aspects of executive
function. The main limitations to our study are: 1) that we
only had access to instruments measuring one of the spe-
cific negative subsymptoms and thus cannot conclude
anything about the specificity of our finding in regard to
the other subsymptoms. 2) that for some patients the clin-
ical assessment of apathy and the neuropsychological test-
ing took place with a time difference and this could
weaken our chances to detect weaker associations.
Conclusion
First we replicated the finding in FEP patients, as was
found in chronic patients, of a significant relationship
between apathy and executive functioning. Second, we
found that apathy in FEP have the same relationship to
the Verbal Fluency test, as reported in other brain disor-
ders, pointing to a common underlying nature of this
symptom across disorders.
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